Document:

License Agreement

 Exhibit 10.1 
 **Text Omitted and Filed Separately with the Securities and Exchange Commission. 
 Confidential Treatment Requested Under 
 17 C.F.R. Sections
200.80(b)(4) and 240.24b-2 
 DATED May 3, 2011 
 (1) THE CHINESE UNIVERSITY OF HONG KONG 
 and 

(2) SEQUENOM, INC. 
  

 
 LICENSE AGREEMENT

  
  

 This Agreement is made on the 3rd day of May 2011 and commences on the same. 

BETWEEN: 
  

	(1)	The Chinese University of Hong Kong, a university established by Statute in The Hong Kong Special Administrative Region (“SAR”) whose registered office
is at Shatin, New Territories, Hong Kong SAR acting in its capacity as the owner of the Invention as defined herein (“University”) and 

  

	(2)	Sequenom, Inc., a Delaware corporation whose principal place of business is at 3595 Johns Hopkins Court, San Diego, CA 92121, USA, and its Affiliates
(“Licensee”). 

 Who together in this Agreement are referred to as the ‘Parties’ and individually as the
‘Party’. 
 WHEREAS: 
  

	(A)	The Invention (as defined below) was invented by Professor Y M Dennis Lo of the Department of Chemical Pathology of University and his research team, including Rossa
W.K. Chiu, Kwan Chee Chan and Wenli Zheng. 

  

	(B)	University is sole owner of the Invention within University Docket No. [...***...], and the corresponding Proprietary IPR (as defined below) therein.

  

	(C)	University wishes to grant to Licensee and Licensee wishes to acquire a licence to use the Invention and the Proprietary IPR therein in accordance with the provisions
of this Agreement. 

 IT IS HEREBY AGREED as follows: 

 

	1	Definitions 

 In this
Agreement, unless the context clearly otherwise requires, the following words and expressions shall have the following meanings and all defined terms shall apply to their singular and plural forms, as applicable: “Including” means
‘including without limitation’. “H/herein”, “hereof”, “hereunder” or similar expressions refer to this Agreement. “Clause” means the referenced clause in this Agreement. 

 

	 	1.1	“Affiliate” means any entity, which, whether through ownership of voting shares or securities, by contract of otherwise, directly or indirectly
controls, is controlled by, or is under the common control with a Party. 

  

	 	1.2	“Commencement Date” means the date set forth above; 

  

	 	1.3	“Combined Product” means Licensed Product incorporated with, in or combined with any other product supplied by Licensee. For the avoidance of doubt,
General-Use Reagents which may be used in conjunction with a Licensed Product are not included within this definition. 

  

	 	1.4	“Expenses” means all costs and expenses incurred for processing, defending from invalidation attacks or maintaining any one of the Prospective Patents
(as defined below) in a designated Patent Jurisdiction (as defined below) and includes those costs and expenses referred to in Clauses 8.1, 8.2, 8.3, 8.4, 8.5 and 8.6 as payable by Licensee. 

  
  

Page 1 
 ***
Confidential Treatment Requested 

	 	1.5	“Information” means information relating to the Invention and any other technical information of University. 

 

	 	1.6	“Intellectual Property Rights” (“IPR”) means any rights including but not limited to patents, know-how, confidential information, trade
secret, industrial design, data copyrights, trademarks, service marks, trade names, logos and the goodwill associated therewith and all rights or forms of protection having equivalent or similar effect (whether registered, unregistered or being
capable of being registered). 

  

	 	1.7	“Invention” means the invention disclosure and patent applications which were invented by Research Team and owned by University prior to the
Commencement Date and listed in Schedule 2 hereto, and all underlying or related Proprietary IPR owned by University prior to the Commencement Date, including the Prospective Patent. 

 

	 	1.8	“License Issue Fee” means the consideration to be paid by Licensee to University in accordance with Clause 5.1.1 of this Agreement.

  

	 	1.9	“Licensed Field of Use” means any prenatal (fetal or maternal) diagnostics and/or prenatal (fetal or maternal) prognostics and/or prenatal (fetal or
maternal) analysis and/or prenatal (fetal or maternal) research, for use with any and all types of technology platforms or uses, other than for the purpose of promoting sex selection followed by gender-specific abortion without a medical reason.

  

	 	1.10	“Proprietary IPR” means any and all underlying Intellectual Property Rights subsisting in the Invention solely owned by University, or
University’s interest in Invention co-owned prior to the Commencement Date by University and another party. 

  

	 	1.11	“Prospective Patent” means any and all patents and patent applications specified in Schedule 2, including any grants, divisions, continuations,
continuations-in-part, reissues, re-examinations and extensions (collectively called “maintenance”) of all such patents claiming priority therefrom, including any foreign counterparts thereof, and more particularly described in Clause 8
below (and any reference to “Prospective Patent” shall include any and all of them) as well as renewals thereof, excluding any rights that extend to Hong Kong SAR. 

 

	 	1.12	“Licensed Product” means the Invention as embodied in any product, service or process that is developed or produced by Licensee and/or its
Sub-Licensee, in the Licensed Field of Use, and that employs or is produced by the practice of any Invention or whose manufacture, use, practice, sale, offer for sale, or importation would constitute, but for the license University grants to
Licensee under this Agreement, an infringement of any rights afforded by the Invention. For the avoidance of doubt, General-Use Reagents which may be used in conjunction with a Licensed Product are not included within this definition.

  

	 	1.13	General-Use Reagent means any product, service or process that relates to general genetic analysis methods and/or products and that does not employ or is not
produced by the practice of any Invention or whose manufacture, use, practice, sale, offer for sale, or importation would not constitute an infringement by Licensee or its Sub-Licensee of any rights afforded by the Invention.

  

	 	1.14	 “Net Sales Value” means the aggregate consideration, including royalties (excluding up-front

  
  

Page 2 

	 	
payments, milestone payments, refunds, credits, grant or research funding or equity investment) which are received by Licensee, directly or by Licensee from a Sub-Licensee, from the sale, leasing
or other commercial disposition of a Licensed Product, and based on the invoiced price of Licensed Product sold by the Licensee in arm’s-length transactions, or, where the sale is not at arm’s length, the price that would have been so
invoiced if it had been at arm’s length, less normal trade discounts actually granted, insurance, freight, or any relevant tax, duties or similar government levies. 

 

	 	1.15	“Patent Jurisdictions” means convention countries and/or regions in which the Prospective Patent has been filed or granted or to be filed or granted
and for which the application, prosecution, defense from invalidation attacks and maintenance will be made at the Licensee’s expense. 

  

	 	1.16	“Research Team” means Professor Y M Dennis Lo of the Department of Chemical Pathology of The Chinese University of Hong Kong and his research team.

  

	 	1.17	“Standard Terms and Conditions” or T&C’s means the terms and conditions in Schedule 1 annexed hereto. 

 

	 	1.18	“Sub-Licensee” means a sub-licensee who has a valid and subsisting license granted to it by Licensee for the exploitation of the Licensed Product.

  

	 	1.19	“Term” – see Section 3.1. 

  

	 	1.20	“Territory” means any and all countries or jurisdictions in the world excluding Hong Kong SAR. 

 

	 	1.21	“PRC” means the People’s Republic of China, excluding Hong Kong SAR. 

 

	 	1.22	“USA” means the United States of America. 

  

	2	Grant of License 

  

	 	2.1	University hereby grants to Licensee, for the Term and subject to the provisions of this Agreement, an exclusive license to its interest in the Invention within
University Docket No. [...***...] with the right to sublicense, subject to Clause 4, to apply and exploit the use of the Invention, to make, authorize the making of, have made, use, process, supply, sell, offer to sell, lease, otherwise
commercially dispose of, import and export or otherwise exploit in any manner the Licensed Product and/or the Combined Product in the Licensed Field of Use within the Territory. Licensee shall be responsible for the safety and quality of the
Licensed Product. 

  

	 	2.2	In respect of any Proprietary IPR in the Invention not covered by the Prospective Patent, the license under Clause 2.1 is non-exclusive.

  

	 	2.3	In respect of the Prospective Patent, the license under Clause 2.1 is exclusive, subject to Clause 2.4. 

 

	 	2.4	 University reserves the right to use and develop the Invention and the Prospective Patent worldwide solely for academic, research and publication
purposes at all times provided that University provides a copy of any manuscript to Licensee, at the time of submission, for any publications submitted to a journal indexed by the Institute of Scientific Information; and to extend

  
  

Page 3 
 ***
Confidential Treatment Requested 

	 	
the academic, research and publication rights, set forth above, to other collaborating academic organizations in whatever countries. 

 

	 	2.5	University shall, if requested by Licensee, execute and file applications (in the prescribed form) to register or provide notice to the relevant patents
administrators of the transaction contemplated by this Agreement in accordance with relevant laws or regulations, provided that the Licensee: 

  

	 	2.5.1	will, together with each request made to University, provide to University a duly executed irrevocable power of attorney in favor of University pursuant to
relevant local laws, to enable University to remove such registration or notice to the relevant patents administration promptly upon the termination or early termination of the license granted in this Agreement or any part of it, or upon the
abandonment by Licensee of any Prospective Patent under Clause 8.7; 

  

	 	2.5.2	bear all costs and expenses in connection with the requested registration or notice, as well as the removal of such registration or notice, including but not
limited to University’s expenses in consulting its own legal advisers about Licensee’s request and attending to the filing and removal of the registration or notice. 

 

	3	Term of License 

  

	 	3.1	 The license in Clause 2.1 shall be effective and commence from the Commencement Date and shall expire concurrently with the last-to-expire
Prospective Patent or on the 20th anniversary of the
Commencement Date, whichever is the later, unless terminated earlier under the terms of this Agreement (the “Term”). 

  

	4	Sub-Licensee 

  

	 	4.1	For the License granted in Clause 2.1 and/or 2.2, Licensee shall be entitled to grant sub-licenses of its rights thereunder to any person or entity subject to
Clause 5.3. However, Licensee shall ensure that each sub-license includes obligations on the Sub-Licensee at least as restrictive as the obligations imposed on Licensee under this Agreement, excluding any economic term, which may be freely
negotiated between the Licensee and Sub-Licensee, and that: 

  

	 	4.1.1	The terms and conditions of any sub-license shall prohibit further sub-licensing. 

 

	 	4.1.2	The sub-license shall expressly provide that, to the extent permissible under the law, University as owner or co-owner of the Invention may directly enforce the
terms of the sub-license against Sub-Licensee as if it were a party to the sub-license. 

  

	 	4.1.3	Sub-Licensee shall not, directly or indirectly, during the term of the Sub-license or thereafter challenge the ownership and/or any rights of University in the
Invention, including any Proprietary IPR in respect of the Invention, the Prospective Patent, and the validity thereof. 

  

	 	4.2	Any such sub-license shall also expressly include provisions for it to transfer directly to University in the case of termination of this Agreement for any
reason, but University shall not be bound to accept such transfer if the sub-license contains terms or clauses not acceptable to University in 

  
  

Page 4 

	 	
which case the sub-license may be terminated by University at its sole discretion, provided, however, that University shall assume the sub-license if the University has approved it in writing
before or after its execution. University must assume a sub-license only if the version of the sub-license as entered into between Licensee and Sub-Licensee is in all material respects the same as that submitted to University for approval.

  

	 	4.3	Except as provided for in Clause 4.2, all sub-licenses shall terminate automatically on the termination of this Agreement for any reason. Within [...***...] days
of the final execution of any sub-license agreement the Licensee shall provide to University a true copy of it. 

  

	 	4.4	The Licensee shall be responsible for any breach of the sub-license by the Sub-Licensee, with respect to Sub-Licensee’s obligation to make any payments to
Licensee, as if the breach had been that of Licensee under this Agreement, and University shall be at liberty to terminate this Agreement except that University shall not terminate this Agreement if the Licensee makes good any shortfall in payment
by its Sub-Licensee within [...***...] days of that breach, without prejudice to the right of University to seek indemnity from Licensee, which Licensee hereby agrees to provide, against any loss, damages, costs, claims or expenses which are awarded
against or suffered by University as a result of any such breach by the Sub-Licensee. 

  

	 	4.5	In the event that a Sub-Licensee commits a breach of any of its other obligations under the sub-license agreement (“Defaulting Sub-Licensee”), Licensee
shall use all reasonable efforts to enforce the terms of the relevant sub-license agreement against the Defaulting Sub-Licensee. If the Defaulting Sub-Licensee’s breach continues for [...***...] days after University’s written notice to
Licensee, and if Licensee does not within an additional period of [...***...] days from, the end of the aforesaid [...***...] day period (or such longer period as University in its sole discretion may grant taking into consideration the nature and
seriousness of the Defaulting Sub-Licensee’s breach on a case by case basis), provide evidence to satisfy University that Licensee has taken legally reasonable action under the circumstances to remedy the Defaulting Sub-Licensee’s breach
(including, without limitation, commencement of legal proceedings by Licensee against the Defaulting Sub-Licensee to enforce the terms of the sub-license agreement, or the provision of local legal advice, obtained at Licensee’s expense from
counsel of its choosing, and reasonably acceptable to University, indicating that Licensee has taken legally reasonable action to deal with the Defaulting Sub-Licensee’s breach) then unless expressly agreed to in writing by University, the
sub-license granted to Sub-Licensee shall be terminated by Licensee. In any event, Licensee shall indemnify University against all third party claims, demands, actions, suits, damages, penalties, liabilities, judgments, costs (including legal costs
and attorney charges) and expenses assessed against or incurred by University as a result of the breach by the Defaulting Sub-Licensee, even if the relevant sub-license is terminated by Licensee. 

 

	5	Payments 

  

	 	5.1	In consideration of the granting of license by University, Licensee shall pay to University: 

 

	 	5.1.1	 a non-refundable and non-recoupable license issue fee of [...***...] US dollars (US

  
  

Page 5 
 ***
Confidential Treatment Requested 

	 	
$[...***...]) (the “License Issue Fee”), of which [...***...] US dollars (US $[...***...]) shall be due within [...***...] days of the execution of this Agreement and another
[...***...] US dollars (US $[...***...]) which shall be due [...***...] from the Commencement Date. 

  

	 	5.1.2	a) subject to the provisions of Clause 5.6, the royalty, on Net Sales Value, in respect of each application use, process, supply and/or sale of Licensed Product
during the term of the License shall be [...***...] ([...***...]%) percent of Net Sales Value of Licensed Products (subject to the formula set out in Clause 5.4 in cases where Licensee is required to pay to third parties royalties with respect to
Licensed Product) (the “Royalties”). 

 b) (i) during the Term, the royalty on Net Sales Value in
respect of each sale of a non-invasive, prenatal, circulating cell-free, fetal nucleic acid-based trisomy 21 test, for United States sales only (the “US T 21 Test”), shall be an additional [...***...] percent ([...***...]%) of Net Sales
Value on such “US T 21 Test” (the “US T 21 Test Royalty”). 
 (ii) The US T 21 Test Royalty
shall not be subject to the provisions of Clause 5.4 regarding royalty stacking and non-cumulation of royalties. Accordingly, the [...***...]% will be added to whatever the royalty rate would otherwise be. This royalty rate may range from
[...***...]% to [...***...]%. With the addition of the [...***...]% US T 21 Test Royalty, that rate would therefore range between [...***...]% and [...***...]%. Royalty payments attributable to the [...***...]% and the [...***...]% to [...***...]%
components will be individually itemized in statements from Licensee to Licensor. 
 (iii) The US T 21 Test
Royalty shall expire upon a cumulative royalty payment attributable to this [...***...]% of Net Sales Value to University, during the Term, of [...***...] US dollars (US $[...***...]). For the avoidance of doubt, Licensee does not have an obligation
to pay the full $[...***...], or any portion thereof, except as incurred based on actual Net Sales during the Term and subject to section d) below, 
 (iv) The US T 21 Test Royalty will apply to the US T 21 Test, regardless of whether or not the Inventions within University Docket No. [...***...] apply to the US T 21 Test. Solely for purposes of this
Section 5.1.2 b), the term “Licensed Product” in the definition of Net Sales Value shall be replaced with the term “US T 21 Test.”
 c) On the Commencement Date, Licensee shall grant to The Chinese University of Hong Kong Foundation Limited, an Affiliate of the University, a Warrant in the form attached hereto as Exhibit A (the
“Warrant”) to purchase from the Licensee up to 200,000 shares of common stock of the Licensee. The purchase price for each share of the common stock purchasable under the Warrant shall be equal to the closing price of Licensee’s
common stock on the Commencement Date as reported on The Nasdaq Global Market. 
 d) The provisions of Sections 5.1.1 and 5.1.2
b) and c) shall survive any termination of this license by Licensee, unless such termination is due to a material breach of this Agreement or of the Sponsored Research Agreement (No.TS116377) between University and Licensee. 

 

	 	5.2	For the avoidance of doubt, 

  

	 	5.2.1	 the Royalties, including but not limited to Minimum Guarantees (as defined in Clause 5.5)

  
  

Page 6 
 ***
Confidential Treatment Requested 

	 	
shall be payable by the Licensee to University in accordance with the terms of this Agreement throughout the Term of this Agreement in respect of the production, distribution, sale and/or use of
the Licensed Product anywhere in the Territory. 

  

	 	5.2.2	Licensee has to pay the Minimum Guarantees in accordance with Clause 5.5 herein regardless of the status of any individual Prospective Patent. Licensee’s
obligation to pay Minimum Guarantees is not abated by the occurrence of any event, including but not limited to the expiry or invalidation of any issued patent or any claim therein, the unsuccessful application of any patent application, or the
abandonment of any Prospective Patent by Licensee under Clause 5.5 of this Agreement. 

  

	 	5.2.3	The Royalties, subject to Clause 5.4, Minimum Guarantees and Sub-License Royalties (as defined below) must be paid in full in accordance with the provisions in
Clause 5 of this Agreement. Royalties shall be paid [...***...], and shall be in arrears [...***...] days after the last day of [...***...] in accordance with Clause 6.1. 

 

	 	5.3	Licensee agrees to pay University a sub-licensing royalty as set forth below (the “Sub-License Royalties”): 

 

	 	5.3.1	Licensee shall pay University [...***...] ([...***...]%) percent of the Net Sales Value received by Licensee from the Sub-Licensees, (subject to the formula set
out in Clause 5.4 in the case of Combined Products and/or where the Licensee or the Sub-Licensee is required to pay to third parties royalties with respect to Licensed Product and the total sum of royalties to be paid to University and third parties
would exceed [...***...] ([...***...]%) percent of the Net Sales Value of the Licensed Product). 

  

	 	5.3.2	Licensee shall pay University [...***...] ([...***...]%) percent of all one-time payments (including up-front payments and milestone payments) received by
Licensee from a Sub-Licensee. 

  

	 	5.4	For calculation of Royalties and Sub-License Royalties:- 

  

	 	5.4.1	For Combined Product wherein the Licensed Product is not priced separately, the Net Sales Value of the Combined Product shall be:- 

 

	 	(i)	in the case where both the Licensed Product and the other product or products are available in the market as stand-alone products, that proportion of the
price of the Combined Product which is attributable to the Licensed Product by using the following formula: 

 A = market price of Licensed Product in the territory of sale
 B =
market price of other product(s) in the territory of sale
 C = price of Combined Product in the territory of
sale
 Net Sales Value = (A / (A+B)) x C; 

 

	 	(ii)	in the case where the Licensed Product is available in the territory of sale as stand-alone product but any of the other products is not, the market price of the
Licensed Product in the territory of sale as a stand-alone product; or 

  

	 	(iii)	 in the case where the Licensed Product is not available in the territory of sale as stand-alone product, then the market price of the Licensed
Product shall be the 

  
  

Page 7 
 ***
Confidential Treatment Requested 

	 	
average per unit price of the Licensed Product in other territories in which it is available as a stand-alone product. 

 

	 	(iv)	in the case where the Licensed Product is not available for sale as a stand-alone product anywhere in the world, University and Licensee shall negotiate in good faith
the price to be treated as the market price of the Licensed Product in the territory of sale. 

  

	 	5.4.2	If in any jurisdiction within the Territory Licensee is required to pay to third parties royalties with respect to Licensed Product, including Combined Products,
under agreements for patent rights which Licensee determines are necessary or desirable to license or acquire with respect to such Licensed Product, and the total sum of royalties to be paid by Licensee to University and third parties for that
Licensed Product or Combined Product would exceed [...***...] ([...***...]%) percent of the Net Sales Value of that Licensed Product or Combined Product in that jurisdiction for any year within the Term of this Agreement, the royalties to be paid to
University for that Licensed Product or Combined Product in that jurisdiction for that year shall be computed pro rata as follows: 

 Subject to Clause 5.4.3, Licensee will be entitled to deduct from Royalty payments due to University the amount of royalties actually paid to that third party(s), with respect to a particular Licensed
Product or Combined Product and in a particular territory to which third party royalty payments apply. For the avoidance of doubt and by way of illustration, i) if Licensee has to pay [...***...]% of Net Sales Value with respect to a particular
License Product in a particular territory in a particular year as royalties to a third party, the royalties due to University for that Licensed Product for that year shall be [...***...]% ([...***...]% x [...***...]%) of Net Sales Value of such
Licensed Product; ii) if Licensee has to pay [...***...]% of Net Sales Value with respect to a particular Licensed Product in a particular territory in a particular year as royalties to a third party, the royalties due to University for that
Licensed Product for that year shall still be [...***...]% of Net Sales Value. 
 For the purpose of Clause 5.4.2, “third
party” or “third parties” shall not include a party or parties who directly or indirectly control, or are controlled by Licensee, and shall not include Affiliates of Licensee. The term “control” as used herein means the
possession of the power to direct or cause the direction of the management and the policies of an entity, whether through the ownership of a majority of the outstanding voting securities or by contract or otherwise. 

 

	 	5.4.3	 Notwithstanding the foregoing, the operation of Clause 5.4.1 and 5.4.2 shall not accumulatively reduce by more than [...***...] ([...***...]%)
percent the amounts otherwise payable under this Agreement to University with respect to royalties due to University in respect of a particular Licensed Product or Combined Product in a particular territory in any one year as if Clause 5.4.1 and
5.4.2 are not in operation. Also, Licensee’s maximum royalties due to University shall in no event be greater than 6% of Net Sales Value and Licensee’s minimum royalties due to University shall in no event be less than [...***...]% of Net
Sales Value, regardless of all prior independent agreements between the Parties and regardless of the number of independent inventions or other intellectual property rights that may be applicable

  
  

Page 8 
 ***
Confidential Treatment Requested 

	 	
to the Licensed Product. 

  

	 	5.4.4	For the avoidance of doubt, the pro rata adjustment in Clause 5.4.1 and 5.4.2 to Royalties payable to University shall not reduce the amount of the Minimum
Guarantees due pursuant to Clause 5.5. 

  

	 	5.5	Licensee agrees to pay to University fixed sums of minimum annual royalties, subject to Clause 5.6, (“the Minimum Guarantees”), irrespective of whether
or not Net Sales Value is generated, in advance for each year during the Term of the Agreement commencing on 2nd January 2015 (“Minimum Guarantee Year”) as follows:- 

 

			
	 Payment Date
	  	 Minimum Guarantee for the year

	2nd January 2015	  	US$[...***...]
	2nd January 2016 and thereafter	  	US$[...***...]

  

	 	5.6	During each Minimum Guarantee Year, Licensee shall pay University for such year the higher of the applicable (i) Minimum Guarantees, or (ii) actual
Royalties and Sub-License Royalties. 

  

	 	5.7	The cost and expenses referred to in Clause 8.3, the License Issue Fee, Bonus Payments, Royalties, Sub-License Royalties (and Minimum Guarantees, as provided
above), Expenses, the costs referred to in Clause 6.4, any recovery due to University from a patent infringement suit as provided for in Clause 9, and any indemnity to University that Licensee agrees to pay under this Agreement or under any further
agreements in writing to be entered into between University and Licensee pursuant to this Agreement, are the sole and only compensation or payments that will or may be due to University from Licensee hereunder. 

 

	 	5.8	Licensee shall continue to pay Royalties, and Sub-License Royalties in accordance with Clauses 5.1.2 and 5.3 above for as long as Net Sales Value is generated,
and sub-license fee and/or royalties are/is received by Licensee for Licensed Product made; and/or which an order was received, anywhere within the Territory, during the Term of this Agreement and/or the relevant sub-license. Licensee agrees to pay
University the following additional, one-time, non-refundable (except in the case of an uncured breach of a representation or warranty set forth in Paragraphs 1.4, 1.5 or 1.6 of the Standard Terms and Conditions in Schedule 1 by University)
performance bonus amount: (“Bonus Payments”) 

  

	 	5.8.1	US$[...***...] upon [...***...]. 

  

	 	5.8.2	US$[...***...] upon [...***...]. 

  

	 	5.9	 If a court of competent jurisdiction in a particular territory, by a final decision of a court from which no further appeal or reconsideration
can be taken, holds invalid any Prospective Patent or all of the relevant patent claims within a Prospective Patent, Licensee’s obligation to pay Royalties corresponding to the Licensed Product(s) which is(are) covered solely by that patent or
those claims, will cease as of the date of such decision in that jurisdiction and such territory will be excluded from the Territory as defined in Clause 1.20 insofar as the relevant Prospective Patent is

  
  

Page 9 
 ***
Confidential Treatment Requested 

	 	
concerned. Licensee, however, shall pay Royalties that accrued before that decision or that are based on all other patents or claims not involved in that decision. For the avoidance of doubt, if
for a particular product any claim of a Prospective Patent is valid and covers that product, licensee’s obligation to pay Royalties shall not cease. If for a particular product, no claim of any Prospective Patent is valid that covers that
product, licensee’s obligation to pay Royalties for that product in that jurisdiction shall cease. When Licensee’s obligation to pay Royalties in any jurisdiction within the Territory ceases in respect of a Prospective Patent that is
finally declared invalid, this Agreement is deemed to have terminated by expiry in respect of that Prospective Patent in that jurisdiction. 

  

	 	5.10	If in any jurisdiction within the Territory a patent application within the Prospective Patents shall remain pending for longer than [...***...] years from the
date of filing of the said application, Licensee’s obligation to pay Royalties in respect of Licensed Products in that jurisdiction which are covered by only the rights afforded by that pending patent application and no other rights in the
Invention, shall be suspended as from the [...***...] anniversary of the date of filing of the said patent application until a patent issues in respect of any claim in that pending patent application, and such claim covers a Licensed Product. For
the avoidance of doubt, suspension of payment of royalty under this Sub-Clause does not constitute an abandonment of a Prospective Patent by Licensee under Clause 8.7. For further avoidance of doubt and by way of illustration, if an Invention is the
subject of a granted patent in jurisdiction A and a patent application is pending for longer than [...***...] years in jurisdiction B, the suspension under this Sub-Clause shall operate only in respect of the Licensed Products in jurisdiction B and
not in any other jurisdictions within the Territory. 

  

	6	Commercialization Report and Accounting for and Payment of Royalties and Maintenance of Records 

 

	 	6.1	Licensee shall, within [...***...] days after the last day of [...***...], and [...***...], send to University a confidential commercialization report which
comprises: 

  

	 	6.1.1	a report for the preceding [...***...] period to indicate development activities made, milestones achieved, activities performed towards the commercialization of
the Invention, and 

  

	 	6.1.2	a statement specifying royalties payable to University, which shall include the quantities of Licensed Product produced, sold and sales price of Licensed Product
sold or otherwise disposed of, orders received for Licensed Product, the number of sub-licenses granted and details of fees/royalties received from any Sub-Licensees and a calculation showing the royalties due, and the royalty statement shall be
accompanied by a bankers’ draft for (i) any amount over and above the Minimum Guarantees paid in advance for that year under Clause 5.5; and (ii) the Sub-License Royalties payable under Clause 5.3. There shall be no
cross-collateralization, no accounts shall be offset and no other adjustment shall be made between the Licensed Products or Combined Products or between territories, areas or countries of the Territory unless provided otherwise in this Agreement.

  
  

Page 10 
 ***
Confidential Treatment Requested 

	 	6.2	The first commercialization report, covering the period from Commencement Date to [...***...] shall be due on [...***...]. Each subsequent commercialization
report should cover a period of [...***...] as stipulated in Clause 6.1. 

  

	 	6.3	Licensee also agrees to make and will cause its Sub-Licensees to make a written report to University within [...***...] days after the date of termination or
early termination of this Agreement, stating in such report the number, description and Net Sales Value of all products produced, sold, or otherwise disposed of, and upon which royalties are payable but which were not previously reported to
University. 

  

	 	6.4	Licensee shall keep and will require its Sub-Licensees to keep during the Term and two years thereafter, records or accounts sufficient to enable accurate
calculations of royalties due to University. University shall be entitled to appoint an auditor not employed by the University and reasonably acceptable to Licensee to determine the correctness of any royalty statement or royalties payable or paid
hereunder. The cost of inspection by such auditor shall be borne by University unless the auditor’s report indicates that Licensee has under-reported its sales of Licensed Product and/or receipt of fees/royalties from Sub-Licensees by more than
five (5) percent in which case Licensee shall bear the full cost of such audit, provided such error is not due to Sub-Licensee’s erroneous reporting to Licensee. 

 

	7	Milestones 

 Licensee
agrees to meet the milestones as detailed in Schedule 3. In the event that Licensee does not meet any of the milestones, University may at its discretion elect to terminate the license granted under Clause 2.1 with respect to the relevant Milestones
of this Agreement pursuant to Paragraph 7 of Standard Terms and Conditions. Such termination shall only occur with respect to the specific milestone not met. For example, if a first milestone related to [...***...] is not met, but a second milestone
related to [...***...] is met, termination shall only apply with respect to [...***...]. No indulgence given by University on any particular occasion shall be deemed or construed as a waiver of its right to terminate this Agreement on future
occasions. 
  

	8	Prospective Patent 

  

	 	8.1	Subject to Clauses 8.5 and 8.7, Licensee confirms and agrees that from the Commencement Date, it shall assume financial responsibility, as set forth in Clause
8.3, and shall continue to be financially responsible for the prosecution, defense from invalidation attacks and maintenance of any and all Prospective Patent. University shall at the expense of the Licensee, and in a reasonable manner, pursue,
apply for, prosecute, defend against invalidation attacks and maintain the Prospective Patent in the Patents Jurisdiction and such other territories as may be agreed between the Parties from time to time using counsel of the University’s
choice, and reasonably acceptable to Licensee. 

  

	 	8.2	University has been granted and applied for patent applications set forth in Schedule 2. 

 

	 	8.3	 Licensee agrees to (a) reimburse the University for patent expenses incurred after the

  
  

Page 11 
 ***
Confidential Treatment Requested 

	 	
Commencement Date; and (b) pay for all reasonable and documented expenses and other Invention-related patent expenses that may arise during the term of this Agreement. Said payments to be
made to University within [...***...] days upon presentation of invoice to Licensee. Licensee expressly agrees to and confirms University’s rights under Paragraph 7.2.2 of the Standard Terms and Conditions. 

 

	 	8.4	University may, but is not obliged to, file, prosecute, defend from invalidation attacks and maintain, at the Licensee’s request and expense, additional
patent applications claiming priority from any of the Prospective Patent in the name of University, using counsel of University’s choice, and reasonably acceptable to Licensee. However, should University decide not to file, or prosecute, or
defend from invalidation attacks, or maintain additional patent applications claiming priority from any of the Prospective Patent, University shall provide the Licensee the opportunity to do so, at Licensee’s expense. University shall provide
reasonable assistance to Licensee with respect to the foregoing, without University joining in the contentious proceedings. Such additional patent applications and the subsequent grants, renewals, amendments or restorations thereof shall be treated
as part of the Prospective Patent hereunder. For the avoidance of doubt, this Clause does not apply to any improvement on the Invention not claiming priority from the Prospective Patent, such improvements being not within the scope of the license
granted hereunder. Although, any such improvements shall be covered by the Sponsored Research Agreement to be concurrently executed by the Parties. 

  

	 	8.5	Where University proposes that an additional patent application claiming priority from the Prospective Patent be filed, designated in a PCT patent
application or entered into national phase in any jurisdictions other than the Patents Jurisdiction, Licensee shall be notified in writing of such proposed applications. Licensee shall have the option to accept the financial
responsibility for the Expenses of such applications within [...***...] days of receipt of the notice, in which case the proposed additional applications and the subsequent grants, renewals, amendments or
restorations thereof shall be treated as part of the Prospective Patent hereunder. In the event that Licensee does not notify University within the aforesaid [...***...] day period that it accepts the financial responsibility of any
of the proposed additional patent applications within the period of time prescribed above, University shall have the sole and absolute discretion to file designate or enter the proposed application into the national phase at its own costs
and expenses, and in such case the jurisdiction in which the proposed application is filed, to which it is designated or into which it is entered shall be excluded from the definition of “Territory” under Clause 1.20 hereunder and the
license granted in Clause 2. 

  

	 	8.6	In addition to its financial responsibility, Licensee shall provide reasonable assistance and co-operation in the prosecution, defense from invalidation attacks
and maintenance of Prospective Patent at the request of University. 

  

	 	8.7	 Licensee may, by at least [...***...] days’ advanced written notice, terminate its financial responsibility for the expenses for the
filing, prosecution, defense from invalidation attacks or maintenance of any of the Prospective Patent (“Abandoned Patent”) in any of the Patents Jurisdiction (“Abandoned Jurisdiction”). The notice shall identify the
Abandoned Patent, the Abandoned Jurisdiction and the date the termination is to take effect (which shall not be less than [...***...] days 

  
  

Page 12 
 ***
Confidential Treatment Requested 

	 	
from the date of the service of the notice). The service of such notice on University shall constitute an irrevocable abandonment by Licensee of its license hereunder in the Abandoned Patent, in
the Abandoned Jurisdiction on the effective date stated in the said notice (“Date of Abandonment”) and the Abandoned Jurisdiction shall be excluded from the definition of “Territory” in Clause 1.20 and the license granted in
Clause 2. Upon issuing the notice, and without prejudice to the Licensee’s obligations for the Abandoned Patent that have accrued up to the Date of Abandonment, Licensee shall have no further obligation, rights or interests with respect to
the Abandoned Patent as from the Date of Abandonment, and University shall have the option to continue or not to continue prosecution, defense from invalidation attacks or maintenance of the Abandoned Patent. Licensee and the affected
Sub-Licensee shall, at the request of University, enter into a Novation Agreement with University in respect of any Sub-license in any Abandoned Jurisdiction. 

 

	9	Patent Infringement 

  

	 	9.1	If Licensee learns of the infringement of a Prospective Patent, in any jurisdiction within the Territory, Licensee shall so inform University in writing and
shall provide University with reasonable evidence of the infringement. Licensee may not notify a third party of the infringement of the Prospective Patent, save for its legal advisers, without first obtaining written consent of University, which
consent shall not be unreasonably denied or delayed. Both Parties shall use their reasonable commercial efforts in cooperation with each other to terminate such infringement. 

 

	 	9.2	 Licensee may request that University take legal action against the infringement of the Prospective Patent in any jurisdiction within the
Territory. Licensee shall make that request in writing and include reasonable evidence of the infringement to University. If the infringing activity has not been abated within [...***...] days of that request, University may elect to:
(a) commence suit on its own account; or (b) refuse to bring suit. University shall give written notice of its election to Licensee by the end of the aforesaid [...***...] day after receiving notice of the request from Licensee. Licensee
may thereafter bring suit for patent infringement only if University has elected not to commence suit (“Licensee Action”). University hereby agrees to assist and cooperate with Licensee, at Licensee’s expense (including payment for
University’s expert’s time, and other expenses so long as such expenses are properly documented), to enable Licensee to prosecute and maintain such action. However, University’s agreement to assist Licensee does not extend to
agreement to join or to procure its Affiliates to join in legal or other proceedings as a co-party. Notwithstanding the foregoing, where it is necessary under applicable local law for University or its Affiliates to join in proceedings as a
co-party, Licensee shall seek the express written agreement of University and its Affiliates before doing so, on terms to be agreed with University and its Affiliates on a case by case basis. Licensee shall have the right to settle any Licensee
Action or consent to an adverse judgment thereto, in its sole discretion, except that Licensee may not settle such action by agreeing to the invalidation of a Prospective Patent or any claim therein without University’s prior written consent.
Any recovery obtained as a result of a Licensee Action, whether by judgment, award, decree or settlement, shall first be applied to reimbursement of Licensee’s expenses in bringing such suit or proceeding (including any attorneys, expert and
court 

  
  

Page 13 
 ***
Confidential Treatment Requested 

	 	
fees), and the balance shall be considered to be Net Sales Value, and subject to the royalty payments set forth in Clause 5, and the remaining balance shall be recovered by Licensee as damages.

  

	 	9.3	Subject to Clause 9.2, if University commences or defends any suit or proceedings on its own account, University shall do so at its own expense. University shall
have the right to settle any such action or consent to an adverse judgment thereto, in its sole discretion, except that University may not settle such action by granting the third party any license without Licensee’s prior written consent,
which consent may not be unreasonably withheld or delayed if the license to the third party takes the form of a sub-license with Licensee upon Licensee’s usual commercial terms with other sub-licensees in that jurisdiction. Any recovery
obtained as a result of such action, whether by judgment, award, decree, or settlement, shall first be applied to reimbursement of University’s expenses in bringing such suit or proceeding (including expert, attorneys and court fees), and the
balance shall be [...***...] in all cases which do not result in a sub-license to a third party. If a suit or proceedings results in a sub-license to a third party, then any recovery, whether by judgment, award, decree, or settlement, shall first be
applied to reimbursement of University’s expenses in bringing such suit or proceeding (including expert, attorneys and court fees), and the balance to be shared between University and Licensee according to the provisions in Clause 5.3 herein.

  

	10	Notices and Payments 

  

	 	10.1	Any notices or communication given under this Agreement shall be in English, in writing and delivered by registered post, overnight courier with package tracking
capabilities, by hand, or by facsimile to the Party at its address or fax number set out below or to such other address as may be notified in writing from time to time between the Parties. A notice or communication to University must specify the
Agreement Number TS116379 for identification. Any notices or communication given under this Agreement if sent by registered post, or overnight courier, or by hand shall be deemed to be given at the time and date of receipted delivery to the relevant
address, and if sent by fax, upon receipt by the sender of machine or computer printed confirmation of receipt. 

  

			
	 To University:
	  	The Chinese University of Hong Kong
		  	Room 538, Sino Building
		  	Shatin, New Territories
		  	Hong Kong SAR
		  	Fax No.: +852 2696 1563
		  	Attn: Director, Knowledge Transfer Office
		
	 with a copy to:
	  	Department of Chemical Pathology
		  	The Chinese University of Hong Kong
		  	c/o Prince of Wales Hospital
		  	Shatin

  
  

Page 14 
 ***
Confidential Treatment Requested 

			
		  	New Territories
		  	Hong Kong SAR
		  	Fax No.: +852 2636 5090
		  	Attn: Professor Y M Dennis Lo
		  	          Department of Chemical Pathology
		
	 To Licensee:
	  	Sequenom, Inc.
		  	3595 John Hopkins Court
		  	San Diego, CA 92121
		  	USA
		  	Fax No.: +1 858 202 9201
		  	Attn:       Vice President and General Counsel

  

	 	10.2	All payments to be paid hereunder shall be made in reference to the Agreement Number TS116379 for purpose of identification. All payments to University are to be
made payable to “The Chinese University of Hong Kong”, to be in US dollars and to be sent to the Director of Knowledge Transfer Office at the above address of University or by wire transfer to the following account:

  

			
	 Account Name:
	  	[...***...]
	 Account No.:
	  	[...***...]
	 Swift Code:
	  	[...***...]
	 Name of Bank:
	  	[...***...]
		  	[...***...]
		  	[...***...]

 and shall be paid in full without any deductions, save for such tax as Licensee is legally bound to
withhold. Licensee shall provide reasonable assistance to University, free of charge, to recover any tax so withheld. 
  

	11	Miscellaneous 

  

	 	11.1	“Clause” means clauses in the main part of this Agreement and “Paragraph” means paragraphs in the Standard Terms and Conditions in Schedule
1. 

  

	 	11.2	Heading to clauses and paragraphs are for convenience only and have no legal effect. 

 

	 	11.3	Words importing the singular include the plural and vice versa, words importing a gender include every gender and references to persons include bodies corporate
or incorporate. 

  

	 	11.4	Any schedule to this Agreement is part of it and reference to this Agreement includes reference thereto. In the event that there is any inconsistency between the
Standard Terms and Conditions and the remainder of this Agreement, the latter shall prevail. 

  

	 	11.5	 The terms of this Agreement shall be deemed confidential information under this Agreement and there shall be no public disclosure except with
prior mutual agreement, unless as provided for in this Clause. The Parties shall agree upon a press release to be released within a reasonable 

  
  

Page 15 
 ***
Confidential Treatment Requested 

	 	
period of time after the signing of this Agreement. In the event that a Party is required to publicly disclose the terms of this Agreement pursuant to the rules of any securities exchange or the
U.S. Securities and Exchange Commission, or other regulatory or governmental agency, to which any Party is subject, the Party shall, where legally permissible, give prior written notice to the other Party, redact as much confidential information as
is permitted under such rules and shall agree on all such redactions with the other Party prior to disclosure, except where such agreement may be precluded by advice of legal counsel of a Party. The non-financial terms of this Agreement may be
disclosed to a Sub-licensee or potential Sub-licensee, so long as such disclosure is made under a confidentiality agreement. 

 In
witness whereof this Agreement has been entered into on the day and year first above written. 
  

					
	SIGNED by	 	)	 	
	Name: Ms Sharon Tam	 	)	 	 
	 Title: Director, Knowledge Transfer Office
 for and on behalf of
	 	 )
 )
	 	/s/ Sharon Tam
	THE CHINESE UNIVERSITY OF HONG KONG	 	)	 	
	in the presence of: Tracy Pang	 	)	 	/s/ Tracy Pang
			
	SIGNED by	 	)	 	
	Name: Harry Hixson, Jr., Ph.D.	 	)	 	
	 Title: Chairman and CEO
 for
and on behalf of
	 	 )
 )
	 	/s/ Harry Hixson, Jr.
	SEQUENOM, INC.	 	)	 	
	in the presence of: Sherry Barnes	 	)	 	/s/ Sherry Barnes

  
  

Page 16 

 SCHEDULE 1 
 STANDARD TERMS AND CONDITIONS (the “T&C’s)) 
  

	1.	Ownership of Intellectual Property Rights 

  

	 	1.1	All rights, including Intellectual Property Rights, in the Invention not expressly granted to Licensee in this Agreement shall remain vested in University.

  

	 	1.2	Licensee shall, at the request of University, execute any document necessary to effect or perfect University’s title where applicable, to Intellectual Property
Rights in the Invention. 

  

	 	1.3	In the event that Licensee wishes to pursue intellectual property protection, including but not limited to patent application, for any Licensed Product, Licensee agrees
to acknowledge, preserve and protect University’s where applicable, pre-existing Intellectual Property Rights in such Licensed Product. 

  

	 	1.4	University warrants, represents and covenants to Licensee for the duration of the Term that: (i) University owns all rights, title, and interest, in and to the
Invention within University Docket No. [...***...] and the corresponding Prospective Patent and Proprietary IPR,; (ii) University has the full right and authority to enter into and implement this Agreement; (iii) the implementation
of this Agreement by the Parties, as contemplated herein, will not violate any of the University’s Charter, codes, policies or organizational documents or any law, rule, regulation or judicial or governmental decree or requirement, of the Hong
Kong SAR; (iv) this Agreement has been duly authorized, executed and delivered by University and is a valid, binding and legally enforceable obligation of University; and (v) the execution, delivery, and performance of this Agreement will
not result in a breach of, or violation of, or constitute a default under, any agreement affecting the rights, title, and interest specified in Paragraph 1.4 (i) above and to which University is a party or by which University is bound, and
(vi) the particulars set out in Schedule 2 are true and accurate in all material respects. 

  

	 	1.5	University further represents that with respect to the Invention there are no pending, or, to its actual, present knowledge, threatened, claims for infringement with
respect to the patent, copyright or other proprietary rights of third parties. University further represents that University has the right to license to Licensee all rights licensed hereunder in accordance with the terms set forth herein.

  

	2.	Obligations of Licensee 

  

	 	2.1	Licensee is responsible for the quality and safety of its products. 

  

	 	2.2	Licensee shall use all reasonable efforts and diligence to exploit the Invention and to proceed with the development, manufacture and sale of Licensed Product and to
diligently develop markets for the Licensed Product. 

  

	 	2.3	Licensee will represent the Licensed Product fairly in comparison with competitive products from other suppliers. 

  
  

Page 17 
 ***
Confidential Treatment Requested 

	 	2.4	Licensee shall market the Licensed Product under the name of Licensee or a Sub-Licensee as seller, and not in any way create any impression that University is the
seller of the Licensed Product. 

  

	 	2.5	Each Party shall take all such steps as are reasonably necessary to protect Intellectual Property Rights in the Invention. Each Party shall provide any assistance, if
necessary, to assist the other Party in protection of such rights. 

  

	 	2.6	Licensee shall promptly inform University upon becoming aware of any illegal or unauthorised use of the Invention or any infringement of the Prospective Patent or
Proprietary IPR and Intellectual Property Rights therein. 

  

	 	2.7	Licensee shall comply with all laws regulations and governmental obligations that may from time to time be applicable to the making, use or sale of the Licensed Product
in each part of the Territory. 

  

	 	2.8	Licensee shall be solely responsible for any claims arising or alleged to arise from loss or injury to persons or property caused or suffered in the course of or as a
consequence of the use of the Invention or the supply and sale of the Licensed Product except where such loss or injury are caused by the gross negligence or wilful misconduct of University. 

 

	 	2.9	Licensee shall use its reasonable endeavours to keep the Invention confidential and to prohibit any third party from having access to any confidential information
regarding the Invention. 

  

	 	2.10	Licensee shall not carry out any illegal, deceptive, or unethical practices, whether or not they are to the disparagement of the Invention, Licensed Product or
University, or any other practices which may be detrimental to the Invention, Licensed Product, University or to the public interest. 

  

	3.	Restriction On Use of Name 

Without prior written consent, no right or licenses are granted by either party to the other expressly or by implication to use its name
or any of its trademark, service mark, trade name, logo or symbol or those of any of its employees in any public relations activities or other activities or in connection with any Licensed Product manufactured used or sold by the Licensee or as part
of any corporate name or firm or trade name or for any other purpose. 
  

	4.	Exclusion of Warranties 

  

	 	4.1	Except as set forth in Paragraphs 1.4, 1.5 and 1.6 of these T&C’s nothing in this Agreement shall be construed as a warranty or representation that anything
made, used, sold, or otherwise disposed of under any licence granted in this Agreement is or will be free from infringement of any patent, copyright, trade mark or any other intellectual property right of any third party. 

 

	 	4.2	Except as expressly set forth in Paragraphs 1.4, 1.5 and 1.6 of these T&C’s, University makes no representations and extends no warranties of any kind, either
express or implied. In particular, but without limitation, there are no express or implied warranties of merchantability or 

  
  

Page 18 

	 	
fitness for a particular purpose, or the operation of the Invention under the Prospective Patent will be uninterrupted or error-free or any defects in the Invention will be corrected.

  

	 	4.3	University does not assume any responsibility for any exploitation, use or any product produced, developed and manufactured in accordance with the Invention or for the
sale or use of the product processed, developed and manufactured by Licensee or its Sub-Licensees nor shall University be deemed to make or have made any warranties of any nature whatsoever with respect to the Invention or any product processed,
developed and manufactured under this Agreement. 

  

	5.	Indemnity 

  

	 	5.1	Licensee shall defend, indemnify and hold harmless University (including its officers, directors, employees) from any and all claims, demands, actions, suits, damages,
penalties, liabilities, judgements, cost or expenses (including legal fees) assessed against or incurred by University relating to the use of or other exploitation by Licensee or otherwise in connection with the manufacture, use, provision or sale
of or any other dealing in the Invention or Licensed Product by Licensee and its Sub-Licensee, including breach of sub-license by a Defaulting Sub-Licensee as provided for in Clause 4.5 even if the relevant sub-licence is terminated by Licensee,
except where such loss or injury (i) are caused by the gross negligence or wilful misconduct of University, or (ii) arise from or relate to a breach of the warranties contained in Paragraphs 1.4, 1.5 or 1.6 above. 

 

	 	5.2	University shall defend, indemnify and hold harmless Licensee (including its officers, directors, employees and Sub-Licensees) from any and all claims, demands,
actions, suits, damages, penalties, liabilities, judgments, cost or expenses (including legal fees) assessed against or incurred by Licensee in connection with University’s breach of any of its warranties or representations in Paragraphs 1.4,
1.5 or 1.6 of the T&C’s. 

  

	6.	Limitation of liability 

  

	 	6.1	Subject to Paragraph 5.2 above, University hereby excludes liability to Licensee and its Sub-Licensee for any and all losses or damage of any kind howsoever caused
including losses of profits or other consequential or special losses arising from the use of or inability, unless such inability is due to University’s breach of Paragraphs 1.4, 1.5 or 1.6, to use the Invention by the Licensee and/or its
Sub-Licensee(s), or to any other breach by the University which materially undermines the value of the Invention, and any rights therein and thereto, to Licensee. 

 

	 	6.2	Without prejudice to Paragraph 6.1, University’s liability to the Licensee for all losses or damage of any kind howsoever caused shall be limited to [...***...].

  
  

Page 19 
 ***
Confidential Treatment Requested 

	 	6.3	No action arising out of this Agreement may be brought by either Party more than [...***...] after the cause of action has accrued and has come to the attention of the
aggrieved Party. 

  

	7.	Termination 

  

	 	7.1	This Agreement, and the licenses granted hereunder, shall come into effect on the Commencement Date and, unless terminated earlier in accordance with this Paragraph 7
or relevant provisions of this Agreement, shall continue in force for the Term of Licence as detailed in Clause 3 and this Agreement and the licenses granted hereunder shall terminate automatically by expiry. 

 

	 	7.2	University shall be at liberty in every and any of the following events to terminate this Agreement in totality by written notice: 

 

	 	7.2.1	on failure by Licensee to meet the milestones as detailed in Schedule 3 which continues for at least [...***...] days after University has given notices of that breach;

  

	 	7.2.2	on failure by Licensee to make any payment to be paid hereunder which continues for at least [...***...] days after University has given written notice of that breach;

  

	 	7.2.3	on any attempt by Licensee to assign or otherwise transfer any of its rights under this Agreement other than in accordance with the terms of this Agreement;

  

	 	7.2.4	on cessation of Licensee’s business relating to the exploitation of the Invention, unless such cessation is due to a permitted assignment or transfer of rights
under this Agreement; or 

  

	 	7.2.5	if Licensee goes into liquidation (other than for the purposes of amalgamation or reconstruction) or if a receiver is appointed of its assets and undertaking or any
part of them or any distress execution or other analogous process shall be issued against any property of Licensee. 

  

	 	7.3	Either Party may terminate this Agreement by written notice if the other Party commits a material breach of this Agreement which continues for at least [...***...] days
after the non-defaulting Party has given written notice of that breach and the required remedy. 

  

	 	7.4	Notwithstanding anything to the contrary herein, at any time after [...***...] from the Commencement Date, Licensee shall have the right to early termination of the
Agreement, such right being exercisable by the Licensee giving at least [...***...] days prior written notice to University. 

  

	8.	Effect of Termination 

  

	 	8.1	Paragraphs 1, 3, 4, 5, 6, 8, 11, 12, 13, 14, and 16 of the T&C’s and Clauses 1, 10 and 11 of the main part of the Agreement shall remain in force following
termination or expiration. 

  

	 	8.2	 On termination, the licence granted pursuant to this Agreement and all rights of Licensee under it shall forthwith cease and terminate without
prejudice to any right of either Party which may 

  
  

Page 20 
 ***
Confidential Treatment Requested 

	 	
have accrued up to the date of termination or remedy to sue and recover for any sum then due and to the remedy of either Party in respect of any previous breach of any provision contained in the
Agreement. 

  

	 	8.3	Within a reasonable period of time after expiration or termination of this Agreement or the licences granted hereunder, Licensee undertakes to return to the University
all originals, in particular, the Information and all copies thereof and information in any form containing or covering in any way any part of the Invention and Licensed Product in its possession and/or control or provide evidence of their
destruction. 

  

	 	8.4	Within a reasonable period of time after expiration or termination of this Agreement or the licences granted hereunder, Licensee shall forthwith cease to use the
Invention and Licensed Product and carry on the activities permitted by this Agreement. 

  

	 	8.5	Licensee will pay up all fees, expenses and payments accrued and payable to University up to the date of termination. 

 

	9.	Governmental Obligations 

 Upon
request by University, Licensee agrees to take all reasonable action necessary on its part as licensee to enable University, at University’s expense, to satisfy its governmental obligations and other reporting requirements, if any, relating to
the Invention and/or this Agreement. 
  

	10.	Time and Force Majeure 

  

	 	10.1	Subject to any grace or cure periods and to the provisions of Paragraph 10.2 below, time shall be of the essence. 

 

	 	10.2	Neither Party shall be liable to the other for delay in performance of its obligations hereunder or deemed to be in breach of this Agreement due to causes beyond its
control, including but not limited to acts of God, disease outbreaks, fires, strikes, acts of war, terrorist acts, or intervention by any governmental authority, and each Party will take steps to minimize any such delay. If such an event occurs, the
time set by this Agreement for performance of that obligation by the relevant Party will be extended for the period by which performance is prevented by the event PROVIDED THAT the other Party may terminate this Agreement by notice if such event
continues for more than [...***...]. 

  

	11.	Severability 

 In the event that
any provision or part of this Agreement is held to be invalid, illegal or otherwise unenforceable, this Agreement shall be deemed to be amended by the addition or deletion of wording as appropriate to remove the invalid part or provision but
otherwise to retain the provision and the other provisions of this Agreement to the maximum extent permissible under applicable law. 

  
  

Page 21 
 ***
Confidential Treatment Requested 

	12.	Waiver 

 No indulgence given by
either Party to the other shall be deemed or construed as a waiver of its rights and remedies hereunder. 
  

	13.	No Implied Partnership or Agency 

Nothing in this Agreement shall constitute or be deemed to constitute a partnership between the Parties and neither Party shall have the
authority or power to bind the other Party or to contract in the name of and create a liability against the other Party. 
  

	14.	Governing Law and Jurisdiction 

  

	 	14.1	This Agreement shall be governed by and construed in accordance with the laws of the Hong Kong SAR, excluding conflict-of-law principles that would cause the
application of the laws of any other jurisdiction. 

  

	 	14.2	Should Licensee bring suit under or relating to this Agreement, such suit, any resulting counterclaim, and the Agreement shall be governed by and in accordance with the
laws of the Hong Kong SAR and the Parties hereby agree to submit to the exclusive jurisdiction of the courts of the Hong Kong SAR, without regard to any choice of forum principles that might apply to move the forum to another jurisdiction. Should
University bring suit under or relating to this Agreement, such suit and any resulting counterclaim, and this agreement shall be governed by and construed in accordance with the laws of the Hong Kong SAR and the Parties hereby agree to submit to the
exclusive jurisdiction of any of the state of federal courts of California, Delaware, or the state where Licensee is incorporated or maintains a principal place of business, to be chosen at University’s discretion, without regard to any choice
of forum principle that might apply to move the forum to another jurisdiction. 

  

	15.	Assignment 

 Subject to Clause 4
above, Licensee shall not assign, mortgage, charge or otherwise transfer any rights and obligations under this Agreement (and any attempt to do so will be null and void), without the prior written consent of University, provided, however, that each
Party may assign its rights and obligations hereunder without such consent to an entity that acquires all or substantially all of the business or assets of the party to which this Agreement pertains, whether by merger, reorganization, acquisition,
sale, or otherwise, provided that reasonable prior written notice is given to the other Party and the Assignee shall expressly in writing assume all rights and obligations of Licensee under this Agreement. Upon such assignment, Assignee shall assume
all rights and obligations under this Agreement. Licensee shall procure the Assignee to enter into novation agreements with University and with any Sub-Licensees and shall procure that either Licensee or the Assignee shall bear all reasonable costs
incurred by University (including legal costs and attorney charges) in connection with the novation agreements as well as the 

  
  

Page 22 
  

 
registration or giving of notice to patents administrations and other relevant third parties as necessitated by the assignment. 

 

	16.	Entire Agreement 

  

	 	16.1	This Agreement, including these T&C’s in this Schedules 1, Schedule 2, 3, and Exhibit A attached and incorporated hereto, constitutes the sole, final and
entire agreement between the Parties and supersedes all prior agreements, whether oral or written, representative statements, negotiations and understandings concerning the subject matter of this Agreement and University hereby excludes any implied
terms which may be excluded by contract to the maximum extent permissible under applicable law. 

  

	 	16.2	Amendments or changes to this Agreement must be in writing and signed by duly authorized representatives of the Parties. 

 

	 	16.3	This Agreement has been drafted and executed in English which shall control for all purposes. 

  
  

Page 23 
  

 SCHEDULE 2 
 DESCRIPTION OF INVENTION 
  

													
	 University Ref No. / Disclosure Form Title
	  	Ownership	 	  	Research Funding	 	  	Prospective Patent	 
	 [...***...]
	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  

  
  

Page 24 
 ***
Confidential Treatment Requested 

 SCHEDULE 3 
 MILESTONES 
 [...***...] 

  
  

Page 25 
 ***
Confidential Treatment Requested 

 EXHIBIT A 
 COMMON STOCK WARRANT 
 THE SECURITIES REPRESENTED BY THIS INSTRUMENT AND THE SECURITIES
ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT
WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF IN VIOLATION OF THE SECURITIES ACT OR SUCH STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, PLEDGED, HYPOTHECATED, ASSIGNED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION AND QUALIFICATION WITHOUT AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO COUNSEL FOR THE CORPORATION, THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED. 

 

			
	Warrant No. __	  	200,000 Shares

 WARRANT TO PURCHASE COMMON STOCK 

For good and valuable consideration, Sequenom, Inc., a Delaware corporation (the “Corporation” or the “Company”)
hereby grants and issues to the Chinese University of Hong Kong Foundation Limited (the “Holder”), the right to purchase from the Corporation up to Two Hundred Thousand (200,000) fully paid and nonassessable shares (the “Warrant
Shares”) of the Common Stock, par value $0.001 per share, of the Corporation (“Common Stock”), subject to the terms and conditions set forth in this warrant (the “Warrant”). 

1. Term. This Warrant may be exercised, as set forth in Section 3, at any time and from time to time, on or before the
seventh anniversary of the issuance date of this Warrant. The period during which this Warrant may be exercised, in accordance with this Section 1, shall be referred to as the “Exercise Period.” 

2. Purchase Price. The purchase price for each share of the Common Stock purchasable hereunder shall be _____________
($____) per Warrant Share (subject to adjustment as set forth herein ) (the “Warrant Purchase Price”). 
 3.
Exercise of Warrant. This Warrant may be exercised by the Holder in whole or in part, but not for less than twenty thousand (20,000) Warrant Shares (or such lesser number of Warrant Shares as may at the time of exercise constitute
the maximum number exercisable), and in excess of 20,000 Warrant Shares in increments of 20,000 Warrant Shares (such minimum and incremental numbers being subject to adjustment for stock splits, combinations and the like). This Warrant is
exercisable, subject to the satisfaction of applicable securities laws, at any time during the Exercise Period by the surrender of the Warrant to the Corporation at its principal office together with the Notice of Exercise annexed hereto duly
completed and executed on behalf of the Holder, accompanied by payment in full of the amount of the aggregate Warrant Purchase Price of the Warrant Shares as follows: at the option of the Holder, payment of the Warrant Purchase Price may be made
either by (i) certified check payable to the order of the Corporation, (ii) surrender of certificates then held representing, or deduction from the number 

  
 26 

 
of Warrant Shares issuable upon exercise of this Warrant, of that number of shares which have an aggregate Fair Market Value (as defined below) on the date of exercise equal to the aggregate
Warrant Purchase Price for all Warrant Shares to be purchased pursuant to this Warrant or (iii) by any combination of the foregoing methods. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the
date of its surrender for exercise as provided above, and the person entitled to receive the Warrant Shares issuable upon such exercise shall be treated for all purposes as the holder of record of such shares as of the close of business on such
date. As promptly as practicable on or after such date the Corporation at its expense shall issue and deliver to the person or persons entitled to receive the same a certificate or certificates for the number of Warrant Shares issuable upon such
exercise. In the event that this Warrant is exercised in part, the Corporation at its expense will execute and deliver as promptly as practicable on or after such date a new Warrant of like tenor exercisable for the remaining number of Warrant
Shares for which this Warrant may then be exercised. For purposes of this Warrant, “Fair Market Value” shall mean (i) the last reported sale price per share of the Common Stock on the Nasdaq Stock Market or any national
securities exchange in which such shares of Common Stock are quoted or listed, as the case may be, or (ii) if such shares of Common Stock are not quoted or listed on the Nasdaq Stock Market or any national securities exchange, the fair market
value of such shares of Common Stock, as determined in good faith by the Board of Directors of the Corporation using customary and appropriate valuation methods (and not taking into account any discounts for minority ownership or restrictions on
transfer of the Warrant Shares). 
 4. Fractional Interest. The Corporation shall not be required to issue any
fractional shares on the exercise of this Warrant. In lieu of any fractional share to which the Holder would otherwise be entitled, the Corporation shall make, at the time it delivers the Warrant Shares deliverable upon such exercise, a cash payment
equal to the per share Fair Market Value on the date of exercise multiplied by such fraction. 
 5. Warrant Confers No
Rights of Stockholder. The Holder shall not have any rights as a stockholder of the Corporation with regard to the Warrant Shares prior to actual exercise resulting in the purchase of the Warrant Shares. 

6. Investment Representation. With respect to this Warrant and the Warrant Shares, the Holder represents and covenants to
the Corporation as follows: 
 (a) It is experienced in evaluating and investing in companies engaged in
businesses similar to that of the Corporation; it understands that investment in the Warrant (and any Warrant Shares it acquires) involves substantial risks; it has made detailed inquiries concerning the Corporation, its business and services, its
officers and its personnel; the officers of the Corporation have made available to the Holder any and all written information it has requested; the officers of the Corporation have answered to the Holder’s satisfaction all inquiries made by it;
in making this investment it has relied upon information made available to it by the Corporation; and it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of investment in the
Corporation and it is able to bear the economic risk of that investment. 
 (b) It is acquiring the Warrant and
the Warrant Shares for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof in 

  
 27 

 
violation of the Securities Act. It understands that the Warrant and the Warrant Shares have not been registered under the Securities Act nor qualified under applicable state securities laws.

 (c) It is an “accredited investor” within the meaning of Rule 501 of Regulation D under the
Securities Act. 
 (d) It acknowledges that the Warrant and the Warrant Shares must be held indefinitely unless
they are subsequently registered under the Securities Act or, based on an opinion of counsel to the Holder reasonably satisfactory to the Corporation, an exemption from such registration is available. It has been advised or is aware of the
provisions of Rule 144 promulgated under the Securities Act. 
 The Holder, by acceptance hereof, consents to the placement of
the following restrictive legends, or substantially similar legends, on each certificate to be issued to the Holder by the Corporation in connection with the issuance of such Warrant Shares: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER APPLICABLE STATE SECURITIES
LAWS AND HAVE BEEN TAKEN FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO OR FOR SALE IN CONNECTION WITH ANY DISTRIBUTION THEREOF IN VIOLATION OF THE SECURITIES ACT OR SUCH STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, PLEDGED,
HYPOTHECATED, ASSIGNED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION AND QUALIFICATION WITHOUT AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO COUNSEL FOR THE CORPORATION, THAT SUCH REGISTRATION AND QUALIFICATION ARE
NOT REQUIRED. 
 provided, however, that whenever this Warrant or any Warrant Shares can be freely transferred under the Securities Act
(whether pursuant to Rule 144 thereunder, or otherwise) the Holder of any Warrant or any Warrant Shares shall be entitled to receive from the Corporation, promptly and without expense to such Holder, one or more new certificates for such securities
not bearing such legends. 
 7. Representations and Warranties of the Corporation. The Corporation hereby
represents and warrants to the Holder as follows: 
 (a) Organization. The Corporation is a corporation,
duly organized, validly existing and in good standing in the State of Delaware. 
 (b) Authorization;
Power. The Corporation has all requisite legal power to enter into this Warrant, and to carry out and perform its obligations under the terms of this Warrant. All action on the part of the Corporation necessary for the authorization, execution,
delivery and performance by the Corporation of this Warrant, and the consummation of the transactions contemplated hereby, has been taken. This Warrant is a legally valid and binding obligation of the Corporation, enforceable against the Corporation
in accordance with its terms (except in all cases as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting the enforcement of creditors’ rights generally and except that
the availability of the equitable remedy of specific performance or 

  
 28 

 
injunctive relief is subject to the discretion of the court before which any proceeding may be brought). 
 (c) No Violation. None of the execution and delivery of this Warrant by the Corporation, the consummation of the transactions provided for herein or contemplated hereby by the Corporation, or the
fulfillment by the Corporation of the terms hereof, will (with or without notice or passage of time or both) (a) conflict with or result in a breach of any provision of the articles of incorporation (including, without limitation, any
certificate of designation) or bylaws of the Corporation, (b) result in a default, give rise to any right of termination, cancellation or acceleration or require any consent or approval (other than approvals or consents that have already been
obtained) under any of the terms, conditions or provisions of any note, bond, mortgage, indenture, loan, license, agreement, lease or other instrument or obligation to which the Corporation is a party or by which it or any of its assets may be bound
or (c) violate any law applicable to the Corporation or any of its assets. 
 8. Reservation of Shares; Warrant
Shares to be Fully Paid. The Corporation agrees at all times during the Exercise Period to have authorized and reserved, for the exclusive purpose of issuance and delivery upon exercise of this Warrant, a sufficient number of shares of its
Common Stock to provide for the exercise of the rights represented hereby. The Corporation covenants and agrees that all Common Stock issued upon exercise of this Warrant will, upon issuance in accordance with the terms hereof, be fully paid and
non-assessable and free from preemptive rights and all taxes, encumbrances, liens and charges with respect to the issuance thereof other than the restrictions on sale and transfer set forth herein. 

9. Payment of Taxes and Expenses. The Corporation shall pay any recording, filing, stamp or other U.S. transfer tax which
may be payable in respect of any transfer involved in the issuance of, and the preparation and delivery of certificates (if applicable) representing, (i) any Warrant Shares purchased upon exercise of this Warrant and (ii) new or
replacement warrants in the Holder’s name. 
 10. Adjustment of Warrant Purchase Price and Number of
Shares. In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or
the like, the number and class of shares available under the Warrant in the aggregate and the Warrant Purchase Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Warrant Purchase Price, the
total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided, however, that such
adjustment shall not be made with respect to, and this Section 10 shall not apply to, any Reorganization events set forth in Section 11 below, which events shall instead be governed by the provisions of Section 11. The form of this
Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 
 11.
Reorganization. 
 (a) In the event of, at any time during the Exercise Period, any capital
reorganization, or any reclassification of the capital stock of the Company (other than a change in par value or from par value to no par value or no par value to par value or as a result of a stock

  
 29 

 
dividend or subdivision, split-up or combination of shares), or the consolidation or merger of the Company with or into another corporation (other than a merger solely to effect a reincorporation
of the Company into another state), or the sale or other disposition of all or substantially all the properties and assets of the Company in its entirety to any other person (each a “Reorganization”), the Company shall provide to the
Holder ten (10) days advance written notice of such Reorganization in the manner provided in Sections 14 and 19 below and shall comply with Section 11(b) below. 

(b) In case of any Reorganization, then and in each such case the Holder, upon the exercise hereof at any time after the
consummation of such Reorganization, shall be entitled to receive, in lieu of the Warrant Shares or other stock or securities and property receivable upon the exercise hereof prior to such consummation, the stock or other securities or property to
which the Holder would have been entitled upon such consummation if the Holder had exercised this Warrant immediately prior thereto, all subject to further adjustment as provided in Section 10 hereof. 

12. Distributions. In the event that, at any time or from time to time after the date of this Warrant, the Corporation
shall make or issue, or shall fix a record date for the determination of all eligible holders entitled to receive, a dividend or other distribution with respect to all outstanding shares of Common Stock of the Corporation (other than in connection
with a transaction described in Section 10 or Section 11 hereof) payable in (i) shares of its capital stock, (ii) other securities of the Corporation or any other person or entity, (iii) evidences of indebtedness issued by
the Corporation or any other person or entity, (iv) options, warrants or rights to subscribe for or purchase any of the foregoing, or (v) assets then, in each such case, the Holder shall receive, in addition to the shares of Common Stock
of the Corporation issuable upon the exercise of this Warrant prior to such date, and without the payment of additional consideration therefor, the shares of capital stock, other securities, evidence of indebtedness, options, warrants or other
rights or assets, as the case may be, to which the Holder would have been entitled upon such date as if the Holder had exercised this Warrant on the date hereof and had thereafter, during the period from the date hereof to and including the date of
the actual exercise of this Warrant, retained such shares and/or all other additional stock available to it as aforesaid during such period, giving effect to all adjustments pursuant to this Section 12. The Corporation shall reserve and set
aside, for the life of this Warrant or until it has been exercised in full, all such distributions to which the Holder is entitled to receive pursuant to this Section 12. 
 13. Notice of Adjustments. Whenever any adjustment is made pursuant to Sections 10, 11 or 12 hereof, the Corporation shall deliver a certificate signed by its President or a Vice President
and by its Treasurer, Assistant Treasurer, Secretary or Assistant Secretary, by first-class mail, postage prepaid to the Holder of this Warrant at its address shown on the books of the Corporation, which certificate shall set forth in reasonable
detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated (including a description of the basis on which the Board of Directors made any determination hereunder), and the Warrant
Purchase Price and the number of shares or other consideration issuable upon the exercise of the Warrant after giving effect to such adjustment. The Corporation shall deliver such certificate to each Holder promptly after each adjustment.

  
 30 

 14. Notices of Record Date, Etc. In the event of 

(a) any taking by the Corporation of a record of the holders of its Common Stock for the purpose of determining the
holders thereof who are entitled to receive any shares of Common Stock as a dividend or other distribution or pursuant to a stock split, or 
 (b) any Reorganization event described in Section 11, or 
 (c)
any voluntary or involuntary dissolution, liquidation or winding-up of the Corporation, or 
 (d) any taking by
the Corporation of a record of the holders of its Common Stock for the purpose of determining the holders thereof who are entitled to receive any distribution described in Section 12, 
 then and in each such event the Corporation will mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such record is to be taken for the purpose of such dividend,
distribution or stock split, and stating the amount and character of such dividend, distribution or stock split, or (ii) the date on which any such Reorganization event described in Section 11, distribution contemplated by Section 12
or dissolution, liquidation or winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock of the Corporation shall be entitled to exchange their shares of Common Stock for securities or other
consideration deliverable on such Reorganization event described in Section 11, distribution contemplated by Section 12, dissolution, liquidation or winding-up. 
 15. Loss, Theft, Destruction or Mutilation of Warrant. Upon receipt by the Corporation of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of any Warrant
or stock certificate, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon reimbursement to the Corporation of all reasonable expenses incidental thereto, and upon surrender and cancellation of
such Warrant or stock certificate, if mutilated, the Corporation will make and deliver a new Warrant or stock certificate of like tenor, in lieu of the original Warrant or stock certificate. 

16. Assignment. This Warrant is not transferable or assignable at any time without the Corporation’s prior written
consent, except to any of the Affiliates (as defined below) of the Holder, provided any such transferee or assignee agrees to be bound by the provisions of this Warrant. The Corporation may issue stop transfer instructions to its transfer agent to
prevent such transfer or assignment. Any permitted assignment or transfer of this Warrant must be made in compliance with all applicable federal and state securities laws by the transferor and the transferee (including delivery of investment
representation letters and legal opinions reasonably satisfactory to the Corporation, if requested by the Corporation). Any person or entity acquiring any interest in this Warrant as provided herein shall be deemed a Holder for purposes hereof. As
used herein, the term “Affiliates” shall mean: (a) any entity resulting from a merger or consolidation with Holder; (b) any entity succeeding to the business and assets of Holder; or (c) any entity controlled by, controlling
or under common control with Holder. The Warrant Shares may not be transferred or assigned unless such Warrant Shares are registered under the Securities Act or, based on an opinion of counsel to the Holder reasonably satisfactory to the
Corporation, an exemption from such registration is available. 

  
 31 

 17. Governing Law. This Warrant shall be governed by and construed in
accordance with the laws of the State of California applicable to contracts entered into and to be performed entirely within the State of California, without application of the law of conflicts. Venue for any and all actions or disputes arising out
of this Agreement shall be the County of San Diego, State of California. 
 18. Amendments and Waivers. Any term
of this Warrant may be amended and the observance of the performance of any term of this Warrant may be waived with the written consent of the Corporation and the Holder. Any amendment or waiver effected in accordance with this Section 18 shall
be binding on the Holder, any future Holders and the Corporation. 
 19. Notices. Unless otherwise provided, any
notice required or permitted under this Warrant shall be given in writing and shall be deemed effectively given (i) upon personal delivery to the party to be notified by hand or professional courier service or five (5) days after deposit
with the United States Post Office, by registered or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such party in the Corporation’s records, or, in each case, at such other address as such
party may designate by ten (10) days’ advance written notice to the other parties. 
 20. Attorneys’
Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to any other relief to
which such party may be entitled. 
 21. Severability. In case any one or more of the provisions contained in this
Warrant shall be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. The parties shall endeavor in good faith
negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions. 

22. No Impairment. The Corporation will not, by amendment of its Certificate of Incorporation or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issuance or sale of securities, sale or other transfer of any of its assets or properties, or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder hereunder against
impairment. Without limiting the generality of the foregoing, the Corporation (a) will not increase the par value of the Warrant Shares receivable upon the exercise of this Warrant above the amount payable therefor on such exercise, and
(b) will take all action that may be necessary or appropriate in order that the Corporation may validly and legally issue fully paid and nonassessable Warrant Shares on the exercise of this Warrant in accordance with the terms hereof.

  
 32 

									
	 Dated:
	 	 May 3, 2011
	 		 	 Sequenom, Inc.

					
		 		 		 	By:	 	/s/ Harry F. Hixon, Jr.
				
	 Accepted and Agreed:
	 		 	Name:	 	Harry F. Hixson, Jr., Ph.D.
				
	Chinese University of Hong Kong	 		 	Title:	 	Chairman and CEO
	Foundation Limited	 		 		 	
					
	 By:
	 	Professor Henry N.C. Wong	 		 		 	
					
	 Its:
	 	Director	 		 		 	

 NOTICE OF EXERCISE 
 To:     Sequenom, Inc. 
 (1) The undersigned hereby
elects to purchase ______ shares of Common Stock of Sequenom, Inc., a Delaware corporation, pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price for such shares as provided in the Warrant. 

(2) In exercising this Warrant, the undersigned hereby confirms and acknowledges that the shares of Common Stock are being acquired
solely for the account of the undersigned and not as a nominee for any other party, or for investment, and that the undersigned will not offer, sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not
result in a violation of the Securities Act of 1933, as amended, or any state securities laws. 
 (3) Please issue a certificate
representing said shares of Common Stock in the name of the undersigned: 
 (4) Please issue a new Warrant for the unexercised
portion of the attached Warrant in the name of the undersigned: 
  

					
			
	 	 		 	  
		 		 	(Name)
			
	 	 		 	 
	(Date)	 		 	(Signature)

 FORM OF ASSIGNMENT 

(To be executed upon assignment of Warrant) 
 For value received, _____________________________________ hereby sells, assigns and transfers unto _________________ the attached Warrant [__% of the attached Warrant], together with all right, title and
interest therein, and does hereby irrevocably constitute and appoint ___________________________ attorney to transfer said Warrant [said percentage of said Warrant] on the books of Sequenom, Inc., a Delaware corporation, with full power of
substitution in the premises. 
 If not all of the attached Warrant is to be so transferred, a new Warrant is to be issued in
the name of the undersigned for the balance of said Warrant. 
  

									
	Dated:	 	 	 		 		 	 
		 		 		 		 	NOTE: The above signature should correspond exactly with the name on the face of the attached Warrant.Loan Agreement

 Exhibit 10.2 
 LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY
AGREEMENT (this “Agreement”) dated as of                     , 2011 (the “Effective Date”) between
SILICON VALLEY BANK, a California corporation (“Bank”), and, SEQUENOM, INC., a Delaware corporation (“Parent”) and SEQUENOM CENTER FOR MOLECULAR MEDICINE, LLC, a Michigan limited liability
company (“Sequenom Center”) (each a “Borrower” and collectively “Borrowers”), provides the terms on which Bank shall lend to Borrowers and Borrowers shall repay Bank. The parties agree as follows:

 1 ACCOUNTING AND OTHER TERMS 

Accounting terms not defined in this Agreement shall be construed following GAAP. Calculations and determinations must be
made following GAAP. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 13. All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code
to the extent such terms are defined therein. 
 2 LOAN AND TERMS OF PAYMENT 

2.1 Promise to Pay. Borrowers hereby unconditionally promise to pay Bank the outstanding principal amount of all
Credit Extensions and accrued and unpaid interest thereon as and when due in accordance with this Agreement. 

2.1.1 Revolving Advances. 

(a) Availability. Subject to the terms and conditions of this Agreement, Bank shall make Advances to Parent not
exceeding the Availability Amount. Amounts borrowed hereunder may be repaid and, prior to the Revolving Line Maturity Date, reborrowed, subject to the applicable terms and conditions precedent herein. 

(b) Termination; Repayment. The Revolving Line terminates on the Revolving Line Maturity Date, when the principal
amount of all Advances, the unpaid interest thereon, and all other Obligations relating to the Revolving Line shall be immediately due and payable. 
 (c) Early Termination. Borrowers shall have the option to terminate the Revolving Line, provided Borrowers (i) provide written notice to Bank of their election to terminate the Revolving Line
at least ten (10) Business Days prior to such termination, and (ii) pay to Bank on the date of such termination an amount equal to the sum of (A) all outstanding principal of the Advances plus accrued interest thereon through the
termination date, (B) the Revolving Line Early Termination Fee, plus (C) all other sums, that shall have become due and payable hereunder with respect to the Revolving Line, including Bank Expenses, if any, and interest at the Default Rate
with respect to any past due amounts. 
 2.1.2 Letters of Credit Sublimit. 

(a) As part of the Revolving Line, Bank shall issue or have issued Letters of Credit denominated in Dollars or a Foreign
Currency for a Borrower’s account. The aggregate Dollar Equivalent amount utilized for the issuance of Letters of Credit shall at all times reduce the amount otherwise available for Advances under the Revolving Line. The aggregate Dollar
Equivalent of the face amount of outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit and any Letter of Credit Reserve) may not exceed the lesser of (A) Two Million Dollars ($2,000,000), minus (i) the sum of
all amounts used for Cash Management Services, and minus (ii) the FX Reduction Amount, or (B) the lesser of Revolving Line or the Borrowing Base, minus (i) the sum of all outstanding principal amounts of any Advances (including any
amounts used for Cash Management Services), and minus (ii) the FX Reduction Amount. 
 (b) If, on the
Revolving Line Maturity Date (or the effective date of any termination of this Agreement), there are any outstanding Letters of Credit, then on such date Borrowers shall provide to Bank cash 

  
 1 

 
collateral in an amount equal to one hundred five percent (105%) of the Dollar Equivalent of the face amount of all such Letters of Credit plus all interest, fees, and costs due or to become
due in connection therewith (as estimated by Bank in its good faith business judgment), to secure all of the Obligations relating to such Letters of Credit. All Letters of Credit shall be in form and substance acceptable to Bank in its sole
discretion and shall be subject to the terms and conditions of Bank’s standard Application and Letter of Credit Agreement (the “Letter of Credit Application”). Borrowers agree to execute any further documentation in connection
with the Letters of Credit as Bank may reasonably request. Borrowers further agree to be bound by the regulations and interpretations of the issuer of any Letters of Credit guarantied by Bank and opened for a Borrower’s account or by
Bank’s interpretations of any Letter of Credit issued by Bank for a Borrower’s account, and each Borrower understands and agrees that Bank shall not be liable for any error, negligence, or mistake, whether of omission or commission, in
following a Borrower’s instructions or those contained in the Letters of Credit or any modifications, amendments, or supplements thereto, except for Bank’s gross negligence or willful misconduct. 

(c) The obligation of Borrowers to immediately reimburse Bank for drawings made under Letters of Credit shall be
absolute, unconditional, and irrevocable, and shall be performed strictly in accordance with the terms of this Agreement, such Letters of Credit, and the Letter of Credit Application. 

(d) Borrowers may request that Bank issue a Letter of Credit payable in a Foreign Currency. If a demand for payment is
made under any such Letter of Credit, Bank shall treat such demand as an Advance to Borrowers of the Dollar Equivalent of the amount thereof (plus fees and charges in connection therewith such as wire, cable, SWIFT or similar charges). 

(e) To guard against fluctuations in currency exchange rates, upon the issuance of any Letter of Credit payable in a
Foreign Currency, Bank shall create a reserve (the “Letter of Credit Reserve”) under the Revolving Line in an amount equal to ten percent (10%) of the face amount of such Letter of Credit. The amount of the Letter of Credit
Reserve may be adjusted by Bank from time to time to account for fluctuations in the exchange rate. The availability of funds under the Revolving Line shall be reduced by the amount of such Letter of Credit Reserve for as long as such Letter of
Credit remains outstanding. 
 2.1.3 Foreign Exchange Sublimit. As part of the Revolving Line, Borrowers
may enter into foreign exchange contracts with Bank under which a Borrower commits to purchase from or sell to Bank a specific amount of Foreign Currency (each, a “FX Forward Contract”) on a specified date (the “Settlement
Date”). FX Forward Contracts shall have a Settlement Date of at least one (1) FX Business Day after the contract date and shall be subject to a reserve of ten percent (10%) of each outstanding FX Forward Contract (the “FX
Reserve”). The aggregate amount of FX Forward Contracts at any one time may not exceed ten (10) times the lesser of (A) Two Million Dollars ($2,000,000), minus (i) the sum of all amounts used for Cash Management Services, and
minus (ii) the Dollar Equivalent of the face amount of any outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit and any Letter of Credit Reserve), or (B) the lesser of the Revolving Line or the Borrowing Base,
minus (i) the sum of all outstanding principal amounts of any Advances (including any amounts used for Cash Management Services), and minus (ii) the Dollar Equivalent of the face amount of any outstanding Letters of Credit (including drawn
but unreimbursed Letters of Credit and any Letter of Credit Reserve). The amount otherwise available for Credit Extensions under the Revolving Line shall be reduced by an amount equal to ten percent (10%) of each outstanding FX Forward Contract
(the “FX Reduction Amount”). Any amounts needed to fully reimburse Bank for any amounts not paid by Borrowers in connection with FX Forward Contracts will be treated as Advances under the Revolving Line and will accrue interest
at the interest rate applicable to Advances. 
 2.1.4 Cash Management Services Sublimit. Borrowers may
use the Revolving Line for Bank’s cash management services, which may include merchant services, direct deposit of payroll, business credit card, and check cashing services identified in Bank’s various cash management services agreements
(collectively, the “Cash Management Services”), in an aggregate amount not to exceed the lesser of (A) Two Million Dollars ($2,000,000), minus (i) the Dollar Equivalent of the face amount of any outstanding Letters of
Credit (including drawn but unreimbursed Letters of Credit and any Letter of Credit Reserve), and minus (ii) the FX Reduction Amount, or (B) the lesser of the Revolving Line or the Borrowing Base, minus (i) the sum of all outstanding
principal amounts of any Advances, minus the Dollar Equivalent of the face amount of any outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit and any Letter of Credit Reserve), and minus (iii) the FX Reduction
Amount. Any amounts Bank pays on behalf of a Borrower for any Cash Management Services will be treated as Advances under the Revolving Line and will accrue interest at the interest rate applicable to Advances. 

  
 2 

 2.1.5 Term Loans. 

(a) Availability. Subject to the terms and conditions of this Agreement, during the Draw Period, Bank shall make
one (1) or more term loans (each, a “Term Loan”) available to Borrowers in an aggregate amount up to the Term Loan Amount. Notwithstanding the foregoing, within thirty (30) days after the Effective Date, Bank shall make an
initial Term Loan to Borrower in an amount equal to at least Five Million Dollars ($5,000,000) (the “First Term Loan”), which amount shall be used to finance capital equipment purchases invoiced on or after October 1, 2010. Each Term
Loan following the First Term Loan must be in an amount equal to at least One Million Dollars ($1,000,000), which amounts shall be used to finance capital equipment purchases invoiced on or after the Effective Date. 

(b) Repayment. Borrowers shall repay the Term Loans in thirty three (33) equal installments of principal,
plus accrued but unpaid interest (the “Term Loan Payment”) commencing on September 1, 2012 and continuing on the same day of each month thereafter. Borrowers’ final Term Loan Payment, due on the Term Loan Maturity Date,
shall include all outstanding principal and accrued and unpaid interest under the Term Loans. Once repaid, the Term Loans may not be reborrowed. 
 (c) Mandatory Prepayments. If the Term Loans are accelerated following the occurrence of an Event of Default, Borrowers shall immediately pay to Bank an amount equal to the sum of: (A) all
outstanding principal of the Term Loans plus accrued interest thereon through the prepayment date, (B) the Term Loan Final Payment, (C) if applicable, the Term Loan Prepayment Fee, plus (D) all other sums, that shall have become due
and payable, including Bank Expenses and interest at the Default Rate with respect to any past due amounts. 

(d) Permitted Prepayment of Term Loans. Borrowers shall have the option to prepay all, but not less than all, of
the Term Loans advanced by Bank under this Agreement, provided Borrowers (i) provide written notice to Bank of their election to prepay the Term Loans at least ten (10) Business Days prior to such prepayment, and (ii) pay to Bank on
the date of such prepayment an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued interest thereon through the prepayment date, (B) the Term Loan Final Payment, (C) if applicable, the Term Loan
Prepayment Fee, plus (D) all other sums, that shall have become due and payable hereunder with respect to the Term Loans, including Bank Expenses, if any, and interest at the Default Rate with respect to any past due amounts. Prior to the last
day of the Draw Period, Borrowers shall have the option to terminate the Bank’s commitment to make Term Loans, provided Borrowers (i) provide written notice to Bank of their election to terminate such commitment at least ten
(10) Business Days prior to the termination date, and (ii) pay to Bank on the date of such termination an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued interest thereon through the termination
date, (B) the Term Loan Final Payment, (C) if applicable, the Term Loan Prepayment Fee, plus (D) all other sums, that shall have become due and payable hereunder with respect to the Term Loans, including Bank Expenses, if any, and
interest at the Default Rate with respect to any past due amounts. 
 2.2 Overadvances. If, at any time,
the sum of (a) the outstanding principal amount of any Advances (including any amounts used for Cash Management Services), plus (b) the face amount of any outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit
and any Letter of Credit Reserve), plus (c) the FX Reduction Amount exceeds the lesser of either the Revolving Line or the Borrowing Base, Borrowers shall immediately pay to Bank in cash such excess. 

2.3 Payment of Interest on the Credit Extensions. 

(a) Interest Rate. 
 (i) Advances. Subject to Section 2.3(b), the principal amount outstanding under the Revolving Line shall accrue interest at a floating per annum rate equal to one percentage point
(1.00%) above the Prime Rate, which interest shall be payable monthly in accordance with Section 2.3(f). 

  
 3 

 (ii) Term Loans. Subject to Section 2.3(b), the principal
amount outstanding under each Term Loan shall accrue interest at a per annum rate equal to the Basic Rate, fixed on the Funding Date of each Term Loan, which interest shall be payable monthly in accordance with Section 2.3(f). 

(b) Default Rate. Immediately upon the occurrence and during the continuance of an Event of Default, the
Obligations shall bear interest at a rate per annum which is five percentage points (5.00%) above the rate that is otherwise applicable thereto (the “Default Rate”) unless Bank otherwise elects from time to time in its sole
discretion to impose a smaller increase. Fees and expenses which are required to be paid by Borrowers pursuant to the Loan Documents (including, without limitation, Bank Expenses) but are not paid when due shall bear interest until paid at a rate
equal to the highest rate applicable to the Obligations. Payment or acceptance of the increased interest rate provided in this Section 2.3(b) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of
Default or otherwise prejudice or limit any rights or remedies of Bank. 
 (c) Adjustment to Interest
Rate. Changes to the interest rate of any Credit Extension based on changes to the Prime Rate shall be effective on the effective date of any change to the Prime Rate and to the extent of any such change. 

(d) Computation; 360-Day Year. In computing interest, the date of the making of any Credit Extension shall be
included and the date of payment shall be excluded; provided, however, that if any Credit Extension is repaid on the same day on which it is made, such day shall be included in computing interest on such Credit Extension. Interest shall be
computed on the basis of a 360-day year for the actual number of days elapsed. 
 (e) Debit of Accounts.
Bank may debit any of Borrowers’ deposit accounts, including the Designated Deposit Account, for principal and interest payments or any other amounts Borrowers owe Bank when due. These debits shall not constitute a set-off. 

(f) Interest Payment Date. Unless otherwise provided, interest is payable monthly, (i) with respect to the
Advances, on the last calendar day of each month and (ii) with respect to the Term Loans, on the first calendar day of each month. 
 2.4 Fees. Borrowers shall pay to Bank: 
 (a) With respect
to the Revolving Line, the following: 
 (i) Commitment Fee. A fully earned, non-refundable commitment
fee of One Hundred Thousand Dollars ($100,000), on the Effective Date; Bank acknowledges receipt from Borrowers of a good faith deposit equal to Twenty Five Thousand Dollars ($25,000), which Bank shall apply to the commitment fee on the Effective
Date; 
 (ii) Letter of Credit Fee. Bank’s customary fees and expenses for the issuance or renewal
of Letters of Credit, upon the issuance of such Letter of Credit, each anniversary of the issuance during the term of such Letter of Credit, and upon the renewal of such Letter of Credit by Bank; 

(iii) Revolving Line Early Termination Fee. The Revolving Line Early Termination Fee, if and when due hereunder;

 (b) With respect to the Term Loans, the following: 

(i) Term Loan Prepayment Fee. The Term Loan Prepayment Fee, if and when due hereunder; 

(ii) Term Loan Final Payment. The Final Payment, when due hereunder; and 

(c) Bank Expenses. All Bank Expenses (including reasonable attorneys’ fees and expenses for documentation and
negotiation of this Agreement incurred through and after the Effective Date, when due. 

  
 4 

 2.5 Payments; Application of Payments. 

(a) All payments (including prepayments) to be made by Borrowers under any Loan Document shall be made in immediately
available funds in U.S. Dollars, without setoff or counterclaim, before 12:00 p.m. Pacific time on the date when due. Payments of principal and/or interest received after 12:00 p.m. Pacific time are considered received at the opening of business on
the next Business Day. When a payment is due on a day that is not a Business Day, the payment shall be due the next Business Day, and additional fees or interest, as applicable, shall continue to accrue until paid. 

(b) Subject to Section 2.6(b), Bank shall apply the whole or any part of collected funds against the Revolving Line
or credit such collected funds to a depository account of a Borrower with Bank (or an account maintained by an Affiliate of Bank), the order and method of such application to be in the sole discretion of Bank. Borrowers shall have no right to
specify the order or the accounts to which Bank shall allocate or apply any payments required to be made by Borrowers to Bank or otherwise received by Bank under this Agreement when any such allocation or application is not specified elsewhere in
this Agreement. 
 2.6 Lockbox; Account Collection Services 

(a) Borrowers shall have the right to collect all Accounts, unless and until an Event of Default has occurred and is
continuing. Borrowers shall direct (i) Account Debtors with respect to Borrowers’ Molecular Diagnostics business to remit payments with respect to such Accounts to a lockbox account established with Bank (the “Lockbox”) and
(ii) Account Debtors with respect to Borrower’s Genetic Analysis business to wire transfer payments to a cash collateral account that Bank controls (the “Cash Collateral Account”). 

(b) Provided no Event of Default exists or an event that with notice or lapse of time will be an Event of Default, within
three (3) days of receipt of any amounts by Bank (whether directly from Borrowers, into the Cash Collateral Account, or into the Lockbox), Bank will turn over to Borrowers the proceeds of the Accounts other than any amounts which are then due
and owing to Bank hereunder; provided, however, Bank may, at its election in its good faith business judgment, hold such amount as a reserve, which amounts may be applied by Bank to the outstanding Obligations regardless of whether such Obligations
are then due and payable. 
 3 CONDITIONS OF LOANS 

3.1 Conditions Precedent to Initial Credit Extension. Bank’s obligation to make the initial Credit Extension
is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, such documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate, including, without
limitation: 
 (a) duly executed original signatures to the Loan Documents; 

(b) each Borrower’s Operating Documents and a good standing certificate of each Borrower certified by, with respect
to Parent, the Secretary of State of the State of Delaware and, with respect to Sequenom Center, the Secretary of State of the State of Michigan, of a date no earlier than thirty (30) days prior to the Effective Date; 

(c) duly executed original signatures to the completed Borrowing Resolutions for each Borrower; 

(d) a payoff letter from the Michigan Strategic Fund providing for, on the Effective Date, the payoff in full of all
Indebtedness owing from Borrowers to the Michigan Strategic Fund and the release of all liens or security interests securing such Indebtedness; 
 (e) certified copies, dated as of a recent date, of financing statement searches, as Bank shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated
in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released; 

  
 5 

 (f) the Perfection Certificate of Parent, together with the duly executed
original signatures thereto; 
 (g) evidence satisfactory to Bank that the insurance policies required by
Section 6.5 hereof are in full force and effect, together with appropriate evidence showing lender loss payable and/or additional insured clauses and cancellation notice to Bank (or endorsements reflecting the same) in favor of Bank; and

 (h) payment of the fees and Bank Expenses then due as specified in Section 2.4 hereof. 

3.2 Conditions Precedent to all Credit Extensions. Bank’s obligations to make each Credit Extension,
including the initial Credit Extension, is subject to the following conditions precedent: 
 (a) except as
otherwise provided hereunder, timely receipt of an executed Term Loan Payment/Advance Form; 
 (b) except as
otherwise provided hereunder, timely receipt of an executed Transaction Report; 
 (c) the representations and
warranties in this Agreement shall be true, accurate, and complete in all material respects on the date of the Term Loan Payment/Advance Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall
not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true,
accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the Credit Extension. Each Credit Extension is Borrowers’ representation and warranty on that date that
the representations and warranties in this Agreement remain true, accurate, and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are
qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; and

 (d) in Bank’s sole discretion, there has not been a Material Adverse Change. 

3.3 Covenant to Deliver. Borrowers agree to deliver to Bank each item required to be delivered to Bank under this
Agreement as a condition precedent to any Credit Extension. Borrowers expressly agree that a Credit Extension made prior to the receipt by Bank of any such item shall not constitute a waiver by Bank of Borrowers’ obligation to deliver such
item, and the making of any Credit Extension in the absence of a required item shall be in Bank’s sole discretion. 
 3.4 Procedures for Borrowing. 
 (a) Advances.
Subject to the prior satisfaction of all other applicable conditions to the making of an Advance set forth in this Agreement, to obtain an Advance (other than Advances under Sections 2.1.2 or 2.1.4), Borrowers shall notify Bank (which notice shall
be irrevocable) by electronic mail, facsimile, or telephone by 12:00 p.m. Pacific time on the Funding Date of the Advance. Together with such notification, Borrowers must promptly deliver to Bank by electronic mail or facsimile a completed
Transaction Report executed by a Responsible Officer or his or her designee. Bank shall credit Advances to the Designated Deposit Account. Bank may make Advances under this Agreement based on instructions from a Responsible Officer or his or her
designee or without instructions if the Advances are necessary to meet Obligations which have become due. Bank may rely on any telephone notice given by a person whom Bank believes is a Responsible Officer or designee. 

  
 6 

 (b) Term Loans. Subject to the prior satisfaction of all other
applicable conditions to the making of a Term Loan set forth in this Agreement, to obtain a Term Loan, Borrowers shall notify the Bank (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 p.m. Pacific time on the
Funding date of the Term Loan. Together with such notification, Borrowers must promptly deliver to Bank by electronic mail or facsimile a completed Term Loan Payment/Advance Form executed by a Responsible Officer or his or her designee. Bank may
rely on any telephone notice given by a person whom Bank believes is a Responsible Officer or designee. Bank shall credit Term Loans to the Designated Deposit Account. Bank may make Term Loans under this Agreement based on instructions from a
Responsible Officer or his or her designee or without instructions if the Term Loans are necessary to meet Obligations which have become due. 
 4 CREATION OF SECURITY INTEREST 
 4.1 Grant of
Security Interest. Each Borrower hereby grants Bank, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Bank, the Collateral, wherever located, whether now owned or
hereafter acquired or arising, and all proceeds and products thereof. 
 4.2 Priority of Security
Interest. Each Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral (subject only to Permitted Liens that
may have superior priority to Bank’s Lien under this Agreement). If a Borrower shall acquire a commercial tort claim, such Borrower shall promptly notify Bank in a writing signed by such Borrower of the general details thereof and grant to Bank
in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Bank. 

If this Agreement is terminated, Bank’s Lien in the Collateral shall continue until the Obligations (other than
inchoate indemnity obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as Bank’s obligation to make Credit Extensions has terminated, Bank shall,
at Borrowers’ sole cost and expense, release its Liens in the Collateral and all rights therein shall revert to Borrowers. 
 4.3 Authorization to File Financing Statements. Each Borrower hereby authorizes Bank to file financing statements, without notice to Borrowers, with all appropriate jurisdictions to perfect or
protect Bank’s interest or rights hereunder, including a notice that any disposition of the Collateral, by either Borrower or any other Person, shall be deemed to violate the rights of Bank under the Code, except for dispositions permitted
hereby. 
 4.4 Pledge of Collateral. Parent hereby pledges, assigns and grants to Bank, for the ratable
benefit of Bank, a security interest in all the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities declared or granted in connection
therewith, and all other cash and noncash proceeds of the foregoing, as security for the performance of the Obligations. Upon the occurrence and during the continuance of an Event of Default hereunder, Bank may effect the transfer of any securities
included in the Collateral (including but not limited to the Shares) into the name of Bank and cause new certificates representing such securities to be issued in the name of Bank or its transferee. Parent will execute and deliver such documents,
and take or cause to be taken such actions, as the Bank may reasonably request to perfect or continue the perfection of the Bank’s security interest in the Shares. Unless an Event of Default shall have occurred and be continuing, Parent shall
be entitled to exercise any voting rights with respect to the Shares and to give consents, waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action taken which would be
inconsistent with any of the terms of this Agreement or which would constitute or create any violation of any of such terms. All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of
an Event of Default. Bank reserves the right to take such steps as Bank reasonably determines to perfect Bank’s security interest in the Shares. 

  
 7 

 5 REPRESENTATIONS AND WARRANTIES 

Each Borrower represents and warrants as follows: 

5.1 Due Organization, Authorization; Power and Authority. Borrower is duly existing and in good standing as a
Registered Organization in its jurisdiction of formation and is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of its business or its ownership of property requires that it be qualified except
where the failure to do so could not reasonably be expected to have a material adverse effect on Borrower’s business. In connection with this Agreement, Borrower has delivered to Bank a completed certificate signed by Borrower entitled
“Perfection Certificate”. Borrower represents and warrants to Bank that (a) Borrower’s exact legal name is that indicated on the Perfection Certificate and on the signature page hereof; (b) Borrower is an organization of the
type and is organized in the jurisdiction set forth in the Perfection Certificate; (c) the Perfection Certificate accurately sets forth Borrower’s organizational identification number or accurately states that Borrower has none;
(d) the Perfection Certificate accurately sets forth Borrower’s place of business, or, if more than one, its chief executive office as well as Borrower’s mailing address (if different than its chief executive office);
(e) Borrower (and each of its predecessors) has not, in the past five (5) years, changed its jurisdiction of formation, organizational structure or type, or any organizational number assigned by its jurisdiction; and (f) all other
information set forth on the Perfection Certificate pertaining to Borrower and each of its Subsidiaries is accurate and complete (it being understood and agreed that Borrower may from time to time update certain information in the Perfection
Certificate after the Effective Date to the extent permitted by one or more specific provisions in this Agreement). Bank agrees that the Perfection Certificate shall be deemed to be updated to reflect information provided in any notice delivered by
Borrower to Bank pursuant to Section 7.2 below. If Borrower is not now a Registered Organization but later becomes one, Borrower shall promptly notify Bank of such occurrence and provide Bank with Borrower’s organizational identification
number. 
 The execution, delivery and performance by Borrower of the Loan Documents to which it is a party have
been duly authorized, and do not (i) conflict with any of Borrower’s organizational documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law, (iii) contravene, conflict or
violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or any of its Subsidiaries or any of their property or assets may be bound or affected, (iv) require any
action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained
pursuant to Section 6.1(b)) or (v) constitute an event of default under any material agreement by which Borrower is bound. Borrower is not in default under any agreement to which it is a party or by which it is bound in which the
default could reasonably be expected to have a material adverse effect on Borrower’s business. 
 5.2
Collateral. Borrower has good title to, has rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and clear of any and all Liens except Permitted Liens. Borrower has no deposit
accounts other than the deposit accounts with Bank, the deposit accounts, if any, described in the Perfection Certificate delivered to Bank in connection herewith, or of which Borrower has given Bank notice and taken such actions as are necessary to
give Bank a perfected security interest therein (and upon delivery of such notice and taking such action, the Perfection Certificate will be deemed to be updated with the information contained in such notice). The Accounts are bona fide, existing
obligations of the Account Debtors. 
 The Collateral is not in the possession of any third party bailee (such
as a warehouse) except as otherwise provided in the Perfection Certificate or as permitted pursuant to Section 7.2. None of the components of the Collateral shall be maintained at locations other than as provided in the Perfection Certificate
or as permitted pursuant to Section 7.2. 
 All Inventory is in all material respects of good and
marketable quality, free from material defects. 
 Borrower is the sole owner of the Intellectual Property which
it owns or purports to own except for (a) non-exclusive licenses granted to its customers in the ordinary course of business and other non-perpetual licenses that could not result in a legal transfer of title of the licensed property but that
may be exclusive in respects other than territory and that may be exclusive as to territory only as to discrete geographical areas outside of the United States, 

  
 8 

 
(b) over-the-counter software that is commercially available to the public, and (c) material Intellectual Property licensed to Borrower and noted on the Perfection Certificate (as may be
updated from time to time pursuant to Section 6.8(b)). To Borrower’s knowledge, each Patent which it owns or purports to own and which is material to Borrower’s business is valid and enforceable, and no part of the Intellectual
Property which Borrower owns or purports to own and which is material to Borrower’s business has been judged invalid or unenforceable, in whole or in part. To the best of Borrower’s knowledge, no claim has been made that any part of the
Intellectual Property violates the rights of any third party except to the extent such claim would not reasonably be expected to have a material adverse effect on Borrower’s business. 

Except as noted on the Perfection Certificate (as may be updated from time to time pursuant to Section 6.8(b)),
Borrower is not a party to, nor is it bound by, any Restricted License. 
 5.3 Accounts Receivable. For
any Eligible Account in any Transaction Report, all statements made and all unpaid balances appearing in all invoices, instruments and other documents evidencing such Eligible Accounts are and shall be true and correct and all such invoices,
instruments and other documents, and all of Borrower’s Books are genuine and in all respects what they purport to be. Whether or not an Event of Default has occurred and is continuing, Bank may notify any Account Debtor owing Borrower money of
Bank’s security interest in such funds and verify the amount of such Eligible Account. All sales and other transactions underlying or giving rise to each Eligible Account shall comply in all material respects with all applicable laws and
governmental rules and regulations. Borrower has no knowledge of any actual or imminent Insolvency Proceeding of any Account Debtor whose accounts are Eligible Accounts in any Transaction Report. To the best of Borrower’s knowledge, all
signatures and endorsements on all documents, instruments, and agreements relating to all Eligible Accounts are genuine, and all such documents, instruments and agreements are legally enforceable in accordance with their terms. 

5.4 Litigation. Except as now or hereafter disclosed in Parent’s public filings with the SEC, there are no
actions or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving more than, individually or in the aggregate, Two Hundred Fifty Thousand Dollars
($250,000). 
 5.5 Financial Statements; Financial Condition. All consolidated financial statements for
Parent and any of its Subsidiaries delivered to Bank fairly present in all material respects Parent’s consolidated financial condition and Parent’s consolidated results of operations as of the dates and for the periods presented. There has
not been any material deterioration in Parent’s consolidated financial condition since the date of the most recent financial statements submitted to Bank. 
 5.6 Solvency. The fair salable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities; Borrower is not left with unreasonably small
capital after the transactions in this Agreement; and Borrower is able to pay its debts (including trade debts) as they mature. 
 5.7 Regulatory Compliance. Borrower is not an “investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as
amended. Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower has complied in all material respects with the Federal Fair
Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a “holding company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company” as each term is
defined and used in the Public Utility Holding Company Act of 2005. Borrower has not violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a material adverse effect on its business. None of
Borrower’s or any of its Subsidiaries’ properties or assets has been used by Borrower or any Subsidiary or, to the best of Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any
hazardous substance other than legally. Borrower and each of its Subsidiaries have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Government Authorities that are necessary
to continue their respective businesses as currently conducted, except where failure to obtain or make such consents, declarations, filings or notices could not reasonably be expected to have a Material Adverse Change. 

5.8 Subsidiaries; Investments. Borrower does not own any stock, partnership interest or other equity securities
except for Permitted Investments. 

  
 9 

 5.9 Tax Returns and Payments; Pension Contributions. Borrower has
timely filed or has obtained extensions for filings all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower. Borrower may defer payment
of any contested taxes, provided that Borrower (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted, (b) notifies Bank in writing of the commencement of, and
any material development in, the proceedings, (c) posts bonds or takes any other steps required to prevent the governmental authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a
“Permitted Lien”. Borrower is unaware of any claims or adjustments proposed for any of Borrower’s prior tax years which could result in additional taxes becoming due and payable by Borrower. Borrower has paid all amounts necessary to
fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and Borrower has not withdrawn from participation in, and has not permitted partial or complete termination of, or permitted the occurrence of
any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency.

 5.10 Use of Proceeds. Borrower shall use the proceeds of the Credit Extensions solely as working
capital, to payoff the existing Indebtedness owing to Michigan Strategic Fund, to purchase capital equipment, and to fund its general business requirements and not for personal, family, household or agricultural purposes. 

5.11 Shares. Parent has full power and authority to create a first lien on the Shares of Sequenom Center and no
disability or contractual obligation exists that would prohibit Parent from pledging such Shares pursuant to this Agreement. To Parent’s knowledge, there are no subscriptions, warrants, rights of first refusal or other restrictions on transfer
relative to, or options exercisable with respect to such Shares. Such Shares have been and will be duly authorized and validly issued, and are fully paid and non-assessable. To Parent’s knowledge, the Sequenom Center Shares are not the subject
of any present or threatened suit, action, arbitration, administrative or other proceeding, and Parent knows of no reasonable grounds for the institution of any such proceedings. 

5.12 Full Disclosure. No written representation, warranty or other statement of Borrower in any certificate or
written statement given to Bank, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written statements given to Bank, contains any untrue statement of a material fact or
omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized by Bank that the projections and forecasts provided by Borrower in good faith and based upon reasonable
assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results). 

5.13 Definition of “Knowledge.” For purposes of the Loan Documents, whenever a representation or
warranty is made to Borrower’s knowledge or awareness, to the “best of” Borrower’s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation, of the Responsible
Officers. 
 6 AFFIRMATIVE COVENANTS 

Borrowers shall do all of the following: 

6.1 Government Compliance. 

(a) Maintain their and all their Subsidiaries’ legal existence and good standing in their respective jurisdictions
of formation and maintain qualification in each other jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on a Borrower’s business or operations; provided that the legal existence of
any Subsidiary that is not a Borrower or a guarantor of the Obligations (or whose Shares are pledged hereunder) may be terminated or permitted to lapse, and any qualification of such Subsidiary to do business may be terminated or permitted to lapse,
if, in the good faith judgment of Borrowers, such termination or lapse is in the best interests of Borrowers and their Subsidiaries, taken as a whole. Each Borrower shall comply, and have each Subsidiary comply, with all laws, ordinances and
regulations to which it is subject, noncompliance with which could reasonably be expected to have a material adverse effect on a Borrower’s business. 

  
 10 

 (b) Obtain all of the Governmental Approvals necessary for the performance
by a Borrower of its obligations under the Loan Documents to which it is a party and the grant of a security interest to Bank in all of the Collateral. Borrowers shall promptly provide copies of any such obtained Governmental Approvals to Bank.

 6.2 Financial Statements, Reports, Certificates. Deliver to Bank: 

(a) Borrowing Base Reports. Within thirty (30) days after the last day of each month, (i) aged listings
of German and domestic accounts receivable and accounts payable (by invoice date) (the “Borrowing Base Reports”); 
 (b) Transaction Reports. Within thirty (30) days after the last day of each month and together with the Borrowing Base Reports, a duly completed Transaction Report signed by a Responsible
Officer; 
 (c) Monthly Financial Statements. As soon as available, but no later than thirty
(30) days after the last day of each month, a company prepared consolidated and consolidating balance sheet and income statement covering Parent’s consolidated operations for such month certified by a Responsible Officer and in a form
acceptable to Bank (the “Monthly Financial Statements”); 
 (d) Monthly Compliance
Certificate. Within thirty (30) days after the last day of each month and together with the Monthly Financial Statements, a duly completed Compliance Certificate signed by a Responsible Officer, certifying that as of the end of such month,
Borrowers were in full compliance with all of the terms and conditions of this Agreement, and setting forth calculations showing compliance with the financial covenants set forth in this Agreement and such other information as Bank shall reasonably
request; 
 (e) Monthly Deferred Revenue Reports. If applicable, as soon as available, but no later than
thirty (30) days after the last day of each month, Borrowers’ Deferred Revenue reports; 
 (f)
Annual Audited Financial Statements. As soon as available, but no later than one hundred twenty (120) days after the last day of Parent’s fiscal year, audited consolidated financial statements prepared under GAAP, consistently
applied, together with an unqualified opinion on the financial statements from an independent certified public accounting firm acceptable to Bank in its reasonable discretion; 

(g) Other Statements. Within five (5) days of delivery, copies of all statements, reports and notices made
available to each Borrower’s security holders or to any holders of Subordinated Debt; 
 (h) SEC
Filings. Within five (5) days of filing, copies of all periodic and other reports, proxy statements and other materials filed by Parent with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC or with
any national securities exchange, or distributed to its shareholders, as the case may be. Documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may
be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Parent posts such documents, or provides a link thereto, on Parent’s website on the Internet at Parent’s website address;

 (i) Annual Financial Projections. As soon as available, but no later than sixty (60) days after
the last day of Borrowers’ fiscal year, annual financial projections for the following fiscal year (on a quarterly basis) as approved by Borrowers’ board of directors, together with any related business forecasts used in the preparation of
such annual financial projections; 
 (j) Legal Action Notice. A prompt report of any legal actions
pending or threatened in writing against a Borrower or any of its Subsidiaries that could result in damages or costs to a Borrower or any of its Subsidiaries of, individually or in the aggregate, Two Hundred Fifty Thousand Dollars ($250,000) or
more; 
 (k) Intellectual Property Notice. Prompt written notice of (i) any material change in
the composition of the Intellectual Property, (ii) the registration of any copyright, including any subsequent ownership right of a Borrower in or to any copyright, patent or trademark not previously disclosed in writing to Bank, and
(iii) Borrowers’ knowledge of an event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property; and 

  
 11 

 (l) Other Financial Information. Budgets, sales projections,
operating plans and other financial information reasonably requested by Bank. 
 6.3 Inventory; Returns.
Keep all Inventory in good and marketable condition, free from material defects. Returns and allowances between a Borrower and its Account Debtors shall follow such Borrower’s customary practices as they exist at the Effective Date. Borrowers
must promptly notify Bank of all returns, recoveries, disputes and claims that involve more than Two Hundred Fifty Thousand Dollars ($250,000). 
 6.4 Taxes; Pensions. Timely file, and require each of their Subsidiaries to timely file, all required tax returns and reports or extensions therefor and timely pay, and require each of their
Subsidiaries to timely pay, all foreign, federal, state and local taxes, assessments, deposits and contributions owed by a Borrower and each of its Subsidiaries, except for deferred payment of any taxes contested pursuant to the terms of
Section 5.9 hereof, and shall deliver to Bank, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their
terms. 
 6.5 Insurance. Keep their businesses and the Collateral insured for risks and in amounts
standard for companies in Borrowers’ industry and location and as Bank may reasonably request. Insurance policies shall be in a form, with companies, and in amounts that are satisfactory to Bank. All property policies shall have a lender’s
loss payable endorsement showing Bank as a lender loss payee and waive subrogation against Bank. All liability policies shall show, or have endorsements showing, Bank as an additional insured. All policies (or their respective endorsements) shall
provide that the insurer shall give Bank at least twenty (20) days notice before canceling, amending, or declining to renew its policy. At Bank’s request, each Borrower shall deliver certified copies of policies and evidence of all premium
payments. Proceeds payable under any policy shall, at Bank’s option, be payable to Bank on account of the Obligations. If a Borrower fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required
proof of payment to third persons and Bank, Bank may make all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Bank deems prudent. 

6.6 Operating Accounts. 
 (a) Maintain all of their primary domestic operating and other deposit accounts with Bank and Bank’s Affiliates which accounts shall, within forty-five (45) days from the Effective Date,
represent at least seventy-five percent (75%) of the dollar value of Borrowers’ domestic operating and other deposit accounts at all financial institutions. This Section shall not apply to Borrowers’ investment accounts. 

(b) Provide Bank five (5) days’ prior written notice before establishing any Collateral Account at or with any
bank or financial institution other than Bank or Bank’s Affiliates. For each domestic Deposit Account of a Borrower containing, at any time, a balance of Fifty Thousand Dollars ($50,000) or more, and for each domestic Securities Account, such
Borrower shall cause, within forty-five (45) days after the Effective Date (or the later establishment of such Collateral Account), the applicable bank or financial institution (other than Bank) at or with which any such Collateral Account is
maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Bank’s Lien in such Collateral Account in accordance with the terms hereunder, which Control Agreement may
not be terminated without the prior written consent of Bank. Borrowers shall not be permitted to transfer any of the proceeds of the Credit Extensions to any Collateral Account for which Bank has not received a Control Agreement except with respect
to Permitted Investments. The provisions in this Section 6.6(b) shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of a Borrower’s employees
and identified to Bank by such Borrower as such. Bank agrees not to place a “hold” or deliver a notice of exclusive control, entitlement order, or other similar directions or instructions under any Control Agreement or similar agreements
providing control of any Collateral unless an Event of Default has occurred and is continuing hereunder. 

6.7 Financial Covenants. Maintain at all times, to be tested as of the last day of each month, unless otherwise
noted, on a consolidated and consolidating basis with respect to Borrowers and their Subsidiaries: 

  
 12 

 Minimum Liquidity. Borrowers’ (i) unrestricted cash and
marketable securities (in each case, on deposit with Bank or Bank’s Affiliates and/or subject to a Control Agreement in favor of Bank) plus the Availability Amount shall be equal to or greater than (ii) the sum of all Indebtedness owing
from Borrowers to Bank plus Borrowers’ Operating Liquidity. 
 6.8 Protection of Intellectual Property
Rights. 
 (a)(i) Protect, defend and maintain the validity and enforceability of its Intellectual Property
material to a Borrower’s business; (ii) promptly advise Bank in writing of material infringements of its Intellectual Property material to a Borrower’s business; and (iii) not allow any Intellectual Property material to a
Borrower’s business to be abandoned, forfeited or dedicated to the public without Bank’s written consent. 
 (b) Provide written notice to Bank within thirty (30) days of entering or becoming bound by any Restricted License (other than over-the-counter software that is commercially available to the public.
Borrowers shall use commercially reasonable efforts to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (i) any Restricted License to be deemed “Collateral” and for Bank to have a security
interest in it that might otherwise be restricted or prohibited by law or by the terms of any such Restricted License, whether now existing or entered into in the future, and (ii) Bank to have the ability in the event of a liquidation of any
Collateral to dispose of such Collateral in accordance with Bank’s rights and remedies under this Agreement and the other Loan Documents. 
 6.9 Litigation Cooperation. From the date hereof and continuing through the termination of this Agreement, make available to Bank, without expense to Bank, Borrowers and their officers, employees
and agents and Borrowers’ books and records, to the extent that Bank may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Bank with respect to any Collateral or relating to a
Borrower. 
 6.10 Access to Collateral; Books and Records. Allow Bank, or its agents, at reasonable
times, on one (1) Business Day’s notice (provided no notice is required if an Event of Default has occurred and is continuing), to inspect the Collateral and audit and copy any Borrower’s Books. Such inspections or audits shall be
conducted no more often than once every year unless an Event of Default has occurred and is continuing. The foregoing inspections and audits shall be at Borrowers’ expense, and the charge therefor shall be Eight Hundred Fifty Dollars ($850) per
person per day (or such higher amount as shall represent Bank’s then-current standard charge for the same), plus reasonable out-of-pocket expenses. In the event a Borrower and Bank schedule an audit more than ten (10) days in advance, and
such Borrower cancels or seeks to reschedule the audit with less than ten (10) days written notice to Bank, then (without limiting any of Bank’s rights or remedies), such Borrower shall pay Bank a fee of One Thousand Dollars ($1,000) plus
any out-of-pocket expenses incurred by Bank to compensate Bank for the anticipated costs and expenses of the cancellation or rescheduling. 
 6.11 Formation or Acquisition of Subsidiaries. 
 (a) At the
time that a Borrower forms any direct or indirect domestic Subsidiary or acquires any direct or indirect domestic Subsidiary after the Effective Date, such Borrower shall (i) cause such new Subsidiary to provide to Bank a joinder to the Loan
Agreement to cause such Subsidiary to become a co-borrower hereunder, together with such appropriate financing statements and/or Control Agreements, all in form and substance satisfactory to Bank (including being sufficient to grant Bank a first
priority Lien (subject to Permitted Liens) in and to the assets of such newly formed or acquired Subsidiary), (ii) provide to Bank appropriate certificates and powers and financing statements, pledging all of the direct or beneficial ownership
interest in such new Subsidiary, in form and substance satisfactory to Bank, and (iii) provide to Bank all other documentation in form and substance satisfactory to Bank, which in its opinion is appropriate with respect to the execution and
delivery of the applicable documentation referred to above. Any document, agreement, or instrument executed or issued pursuant to this Section 6.11(a) shall be a Loan Document. 

(b) At the time that a Borrower forms any direct or indirect foreign Subsidiary or acquires any direct or indirect
foreign Subsidiary after the Effective Date, such Borrower shall (i) provide to Bank appropriate certificates and powers pledging sixty-five percent (65%) of the issued and outstanding capital stock,

  
 13 

 
membership units or other securities owned or held of record by such Borrower in such foreign Subsidiary, in form and substance satisfactory to Bank, and (ii) provide to Bank all other
documentation in form and substance satisfactory to Bank, which in its opinion is appropriate with respect to the execution and delivery of the applicable documentation referred to above. Any document, agreement, or instrument executed or issued
pursuant to this Section 6.11(b) shall be a Loan Document. 
 6.12 Post-Close Deliverables. Within
forty-five (45) days of the Effective Date, the following (i) Control Agreements with respect to each domestic Collateral Account; (ii) an Access and Waiver Agreement (or similar) in favor of Bank with respect to Parent’s San
Diego, California leased location; (iii) a bailee letter agreement (or similar) with respect to Sequenom Center’s Grand Rapids, Michigan location; and (iv) the Sequenom GmbH Share Pledge Documents; all in form and content reasonably
acceptable to Bank. To the extent required by the terms and conditions governing the Sequenom Germany Shares, Parent shall cause the books of Sequenom Germany to reflect the pledge of such Shares. 

6.13 Further Assurances. Execute any further instruments and take further action as Bank reasonably requests to
perfect or continue Bank’s Lien in the Collateral or to effect the purposes of this Agreement. Deliver to Bank, within five (5) days after the same are sent or received, copies of all correspondence, reports, documents and other filings
with any Governmental Authority regarding compliance with or maintenance of Governmental Approvals or Requirements of Law that could reasonably be expected to have a material effect on any of the Governmental Approvals or otherwise on the operations
of Borrowers or any of their Subsidiaries. 
 7 NEGATIVE COVENANTS 

No Borrower shall do any of the following without Bank’s prior written consent (not to be unreasonably withheld):

 7.1 Dispositions. Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively,
“Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for: 
 (a) Transfers in the ordinary course of business for reasonably equivalent consideration, including Transfers of Inventory and worn-out or obsolete Equipment; 

(b) Transfers to a Borrower or any of its Subsidiaries from a Borrower or any of its Subsidiaries; 

(c) Transfers of property in connection with sale-leaseback transactions provided that the book value of all such
property so Transferred shall not exceed Two Hundred Fifty Thousand Dollars ($250,000) in any fiscal year; 

(d) Transfers of property to the extent such property is exchanged for credit against, or proceeds are promptly applied
to, the purchase price of other property used or useful in the business of a Borrower or its Subsidiaries; 

(e) Transfers constituting non-exclusive licenses and similar arrangements for the use of the property of a Borrower or
its Subsidiaries in the ordinary course of business and other non-perpetual licenses that could not result in a legal transfer of title of the licensed property but that may be exclusive in respects other than territory and that may be exclusive as
to territory only as to discreet geographical areas outside of the United States; 
 (f) Transfers otherwise
permitted by the Loan Documents; 
 (g) sales or discounting of delinquent accounts in the ordinary course of
business; 
 (h) Transfers associated with the making or disposition of a Permitted Investment; and 

  
 14 

 (i) Transfers in connection with a permitted acquisition of a portion of the
assets or rights acquired for reasonably equivalent consideration. 
 7.2 Changes in Business, Management,
Control, Business Locations, or Jurisdiction of Formation. (a) Engage in any material line of business other than those lines of business conducted by Borrowers and their Subsidiaries on the date hereof and any businesses reasonably
related, complementary or incidental thereto or reasonable extensions thereof. No Borrower will, without prior written notice to Bank: (i) change its jurisdiction of organization, (ii) change its organizational structure or type,
(iii) change its legal name, (iv) change any organizational number (if any) assigned by its jurisdiction of organization, or (v) add any new offices or business locations, including warehouses (unless such new offices or business
locations contain less than Two Hundred Fifty Thousand Dollars ($250,000) in such Borrower’s assets or property) or deliver any portion of the Collateral valued, individually or in the aggregate, in excess of Two Hundred Fifty Thousand Dollars
($250,000) to a bailee at a location other than to a bailee and at a location already disclosed in the Perfection Certificate. If a Borrower intends to deliver any portion of the Collateral valued, individually or in the aggregate, in excess of Two
Hundred Fifty Thousand Dollars ($250,000) to a bailee, and Bank and such bailee are not already parties to a bailee agreement governing both the Collateral and the location to which such Borrower intends to deliver the Collateral, then such Borrower
will first receive the written consent of Bank, and such bailee shall execute and deliver a bailee agreement in form and substance reasonably satisfactory to Bank. Bank agrees not to deliver a notice to a bailee purporting to exercise dominion or
control over any Collateral or any other similar direction or instruction under any bailee agreement with a Borrower unless an Event of Default has occurred and is continuing hereunder. 

7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with
any Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of a Person, except where no Event of Default has occurred and is continuing or would result from such action during the
term of this Agreement: 
 (a) any Subsidiary may merge or consolidate with (i) a Borrower provided that
such Borrower is the surviving entity, and (ii) one or more other Subsidiaries; 
 (b) a Borrower or any
Subsidiary may acquire, all or substantially all of the capital stock or property of another Subsidiary; 
 (c)
such merger, consolidation or acquisition is a Transfer otherwise permitted pursuant to Section 7.1; or 

(d) a Borrower or any Subsidiary may merge or consolidate with, or acquire all or substantially all of the capital stock
or property of another Person, provided that such Borrower or Subsidiary is the surviving entity and there is compliance with Section 6.11, to the extent applicable. 

7.4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so,
other than Permitted Indebtedness. 
 7.5 Encumbrance. Except for Permitted Liens, create, incur, allow,
or suffer any Lien on any of its property, or permit any of its Subsidiaries to do so; except as permitted by Section 7.1, assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do
so; except for Permitted Liens, permit any Collateral not to be subject to the first priority security interest granted herein; or enter into any agreement, document, instrument or other arrangement (except with or in favor of Bank) with any Person
which directly or indirectly prohibits or has the effect of prohibiting Borrower or any Subsidiary from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower’s or any Subsidiary’s
Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition of “Permitted Liens” herein. 
 7.6 Maintenance of Collateral Accounts. Maintain any Collateral Account except pursuant to the terms of Section 6.6(b) hereof. 

  
 15 

 7.7 Distributions; Investments. (a) Pay any dividends or make
any distribution or payment in respect of or redeem, retire or purchase any capital stock other than Permitted Distributions; or (b) directly or indirectly acquire or own any Person, or make any Investment in any Person, other than Permitted
Investments, or permit any of its Subsidiaries to do so, other than Permitted Investments. 
 7.8
Transactions with Affiliates. . Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower, except for (a) transactions that are in the ordinary course of Borrower’s business, upon fair
and reasonable terms that are no less favorable to Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person; or (b) transactions otherwise permitted pursuant to the terms of Section 7 hereof.

 7.9 Subordinated Debt. (a) Make or permit any payment on any Subordinated Debt, except under the
terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof or adversely
affect the subordination thereof to Obligations owed to Bank, except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject. 

7.10 Compliance. Become an “investment company” or a company controlled by an “investment
company”, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve
System), or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair
Labor Standards Act or violate any other law or regulation, if the violation could reasonably be expected to have a material adverse effect on Borrower’s business, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to
withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result
in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 
 8 EVENTS OF DEFAULT 
 Any one of the following shall
constitute an event of default (an “Event of Default”) under this Agreement: 
 8.1 Payment
Default. Borrowers fail to (a) make any payment of principal or interest on any Credit Extension on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which
three (3) Business Day cure period shall not apply to payments due on the Revolving Line Maturity Date or Term Loan Maturity Date). During the cure period, the failure to make or pay any payment specified under clause (a) or
(b) hereunder is not an Event of Default (but no Credit Extension will be made during the cure period); 

8.2 Covenant Default. 
 (a) Borrowers fail or neglect to perform any obligation in Sections 6.2, 6.4, 6.5, 6.6, 6.7, or 6.11, or violate any covenant in Section 7; or 

(b) Borrowers fail or neglect to perform, keep, or observe any other term, provision, condition, covenant or agreement
contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that can be cured, have failed to cure the default within
ten (10) days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the ten (10) day period or cannot after diligent attempts by Borrowers be cured within such ten (10) day period,
and such default is likely to be cured within a reasonable time, then Borrowers shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within such reasonable time period the
failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period). Cure periods provided under this section shall not apply, among other things, to financial covenants or any other
covenants set forth in clause (a) above; 

  
 16 

 8.3 Material Adverse Change. A Material Adverse Change occurs;

 8.4 Attachment; Levy; Restraint on Business. 

(a)(i) The service of process seeking to attach, by trustee or similar process, any funds of a Borrower or of any entity
under the control of a Borrower (including a Subsidiary) on deposit or otherwise maintained with Bank or any Bank Affiliate, or (ii) a notice of lien or levy is filed against any of a Borrower’s assets by any government agency, and the
same under subclauses (i) and (ii) hereof are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made
during any ten (10) day cure period; or 
 (b)(i) any material portion of a Borrower’s assets is
attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents a Borrower from conducting any material part of its business; 

8.5 Insolvency (a) A Borrower is unable to pay its debts (including trade debts) as they become due or
otherwise becomes insolvent; (b) A Borrower begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against a Borrower and not dismissed or stayed within forty-five (45) days (but no Credit Extensions shall be made
while of any of the conditions described in clause (a) exist and/or until any Insolvency Proceeding is dismissed); 
 8.6 Other Agreements. There is, under any agreement to which a Borrower is a party with a third party or parties, (a) any default resulting in a right by such third party or parties, whether
or not exercised, to accelerate the maturity of any Indebtedness in an amount individually or in the aggregate in excess of Two Hundred Fifty Thousand Dollars ($250,000); or (b) any default by a Borrower, the result of which could reasonably be
expected to have a material adverse effect on a Borrower’s business; provided, however, that the Event of Default under this Section 8.6 caused by the occurrence of a default with respect to such agreement shall be cured or waived for
purposes of this Agreement upon Bank receiving written notice from the party asserting such default of the cure or waiver of such default, if at the time of such cure or waiver (i) Bank has not declared an Event of Default under this Agreement
and/or exercised any rights with respect thereto; (ii) any such cure or waiver does not result in an Event of Default under any other provision of this Agreement or any Loan Document; and (iii) in connection with any such cure or waiver,
the terms of any agreement with such third party are not modified or amended in any manner which could in the good faith judgment of Bank be materially less advantageous to Borrowers; 

8.7 Judgments. One or more final judgments, orders, or decrees for the payment of money in an amount, individually
or in the aggregate, of at least Two Hundred Fifty Thousand Dollars ($250,000) (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against a Borrower and the same are
not, within ten (10) days after the entry thereof, discharged or execution thereof stayed or bonded pending appeal, or such judgments are not discharged prior to the expiration of any such stay (provided that no Credit Extensions will be made
prior to the discharge, stay, or bonding of such judgment, order, or decree); 
 8.8 Misrepresentations.
A Borrower or any Person acting for a Borrower makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Bank or to induce Bank to enter this Agreement or any Loan
Document, and such representation, warranty, or other statement is incorrect in any material respect when made; 

8.9 Subordinated Debt. Any document, instrument, or agreement evidencing the subordination of any Subordinated
Debt shall for any reason be revoked or invalidated or otherwise cease to be in full force and effect, any Person shall be in breach thereof or contest in any manner the validity or enforceability thereof or deny that it has any further liability or
obligation thereunder, or the Obligations shall for any reason be subordinated or shall not have the priority contemplated by this Agreement or the applicable Subordination Agreement; or 

  
 17 

 8.10 Governmental Approvals. Any Governmental Approval shall have
been (a) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the ordinary course for a full term or (b) subject to any decision by a Governmental Authority that designates a hearing with respect to any
applications for renewal of any of such Governmental Approval or that could result in the Governmental Authority taking any of the actions described in clause (a) above, and, as to clause (a) or (b) above, such decision or such
revocation, rescission, suspension, modification or non-renewal (i) has, or could reasonably be expected to have, a Material Adverse Change, or (ii) materially adversely affects the legal qualifications of a Borrower or any of its
Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension, modification or non-renewal could reasonably be expected to materially adversely affect the status of or legal qualifications
of a Borrower or any of its Subsidiaries to hold any Governmental Approval in any other jurisdiction. 
 9
BANK’S RIGHTS AND REMEDIES 
 9.1 Rights and Remedies. While an Event of Default occurs
and continues Bank may, without notice or demand, do any or all of the following: 
 (a) declare all Obligations
immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations are immediately due and payable without any action by Bank); 

(b) stop advancing money or extending credit for Borrowers’ benefit under this Agreement or under any other
agreement between Borrowers and Bank; 
 (c) demand that Borrowers (i) deposit cash with Bank in an amount
equal to one hundred five percent (105%) of the Dollar Equivalent of the aggregate face amount of all Letters of Credit remaining undrawn (plus all interest, fees, and costs due or to become due in connection therewith (as estimated by Bank in
its good faith business judgment)), to secure all of the Obligations relating to such Letters of Credit, as collateral security for the repayment of any future drawings under such Letters of Credit, and Borrowers shall forthwith deposit and pay such
amounts, and (ii) pay in advance all letter of credit fees scheduled to be paid or payable over the remaining term of any Letters of Credit; 
 (d) terminate any FX Forward Contracts; 
 (e) settle or adjust
disputes and claims directly with Account Debtors for amounts on terms and in any order that Bank considers advisable, notify any Person owing a Borrower money of Bank’s security interest in such funds, and verify the amount of such account;

 (f) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or
its security interest in the Collateral. Borrowers shall assemble the Collateral if Bank requests and make it available as Bank designates. Bank may enter premises where the Collateral is located, take and maintain possession of any part of the
Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Each Borrower grants Bank a license to enter and occupy any of its premises, without charge,
to exercise any of Bank’s rights or remedies; 
 (g) apply to the Obligations (i) any balances and
deposits of a Borrower it holds, or (ii) any amount held by Bank owing to or for the credit or the account of a Borrower; 
 (h) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral. Bank is hereby granted a non-exclusive, royalty-free license or other right to
use, without charge, a Borrower’s labels, Patents, Copyrights, mask works, rights of use of any name, trade secrets, trade names, Trademarks, and advertising matter, or any similar property as it pertains to the Collateral, in completing
production of, advertising for sale, and selling any Collateral and, in connection with Bank’s exercise of its rights under this Section, Borrowers’ rights under all licenses and all franchise agreements inure to Bank’s benefit;

  
 18 

 (i) place a “hold” on any account maintained with Bank and/or
deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; 

(j) demand and receive possession of a Borrower’s Books; and 

(k) exercise all rights and remedies available to Bank under the Loan Documents or at law or equity, including all
remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof). 
 9.2
Power of Attorney. Each Borrower hereby irrevocably appoints Bank as its lawful attorney-in-fact, exercisable upon the occurrence and during the continuance of an Event of Default, to: (a) endorse Borrower’s name on any checks or other
forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly with Account Debtors, for
amounts and on terms Bank determines reasonable; (d) make, settle, and adjust all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the
Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Bank or a third party as the Code permits. Each Borrower hereby appoints Bank as its
lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the perfection of Bank’s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations
(other than inchoate indemnity obligations) have been satisfied in full and Bank is under no further obligation to make Credit Extensions hereunder. Bank’s foregoing appointment as each Borrower’s attorney in fact, and all of Bank’s
rights and powers, coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Bank’s obligation to provide Credit Extensions terminates. 

9.3 Protective Payments. If a Borrower fails to obtain the insurance called for by Section 6.5 or fails to
pay any premium thereon or fails to pay any other amount which such Borrower is obligated to pay under this Agreement or any other Loan Document, Bank may obtain such insurance or make such payment, and all amounts so paid by Bank are Bank Expenses
and immediately due and payable, bearing interest at the then highest rate applicable to the Obligations, and secured by the Collateral. Bank will make reasonable efforts to provide Borrowers with notice of Bank obtaining such insurance at the time
it is obtained or within a reasonable time thereafter. No payments by Bank are deemed an agreement to make similar payments in the future or Bank’s waiver of any Event of Default. 

9.4 Application of Payments and Proceeds Upon Default. If an Event of Default has occurred and is continuing, Bank
may apply any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Accounts or other disposition of the Collateral, or otherwise, to the Obligations in such order as Bank
shall determine in its sole discretion. Any surplus shall be paid to Borrowers or other Persons legally entitled thereto; Borrowers shall remain liable to Bank for any deficiency. If Bank, in its good faith business judgment, directly or indirectly
enters into a deferred payment or other credit transaction with any purchaser at any sale of Collateral, Bank shall have the option, exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or
deferring the reduction of the Obligations until the actual receipt by Bank of cash therefor. 
 9.5
Bank’s Liability for Collateral. So long as Bank complies with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Bank, Bank shall not be liable or responsible for:
(a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person. Borrowers bear
all risk of loss, damage or destruction of the Collateral. 
 9.6 No Waiver; Remedies Cumulative.
Bank’s failure, at any time or times, to require strict performance by Borrowers of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Bank thereafter to demand strict performance and
compliance herewith or therewith. No waiver hereunder shall be effective unless signed by the party granting the waiver and then is only effective for the specific instance and purpose for which it is given. Bank’s rights and remedies under
this Agreement and the other 

  
 19 

 
Loan Documents are cumulative. Bank has all rights and remedies provided under the Code, by law, or in equity. Bank’s exercise of one right or remedy is not an election and shall not
preclude Bank from exercising any other remedy under this Agreement or other remedy available at law or in equity, and Bank’s waiver of any Event of Default is not a continuing waiver. Bank’s delay in exercising any remedy is not a waiver,
election, or acquiescence. 
 9.7 Demand Waiver. Each Borrower waives demand, notice of default or
dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Bank on which such Borrower
is liable. 
 9.8 Borrower Liability. Either Borrower may, acting singly, request Advances
hereunder. Each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Advances hereunder. Each Borrower hereunder shall be jointly and severally obligated to repay all
Advances made hereunder, regardless of which Borrower actually receives said Advance, as if each Borrower hereunder directly received all Advances. Each Borrower waives (a) any suretyship defenses available to it under the Code or any
other applicable law, including, without limitation, the benefit of California Civil Code Section 2815 permitting revocation as to future transactions and the benefit of California Civil Code Sections 1432, 2809, 2810, 2819, 2839, 2845, 2847,
2848, 2849, 2850, and 2899 and 3433, and (b) any right to require Bank to: (i) proceed against any other Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy. Bank may
exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any other Borrower’s liability. Notwithstanding any
other provision of this Agreement or other related document, until the Obligations have been indefeasibly satisfied in full in cash and Bank no longer has a commitment to make Credit Extensions hereunder, each Borrower irrevocably waives all rights
that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Bank under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any
other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit
from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise. Any agreement providing for indemnification, reimbursement
or any other arrangement prohibited under this Section shall be null and void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for Bank and such payment shall be promptly
delivered to Bank for application to the Obligations, whether matured or unmatured. 
 10 NOTICES

 All notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or
any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or
certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail or facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with all
charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Bank or Borrowers may change their
mailing or electronic mail address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10. 
  

	 	 If to Borrowers:
	 Sequenom, Inc. 

	 	     
	 3595 John Hopkins Ct. 

	 	     
	 San Diego, CA 92121 

	 	     
	 Attn: Paul V. Maier 

	 	     
	 Fax: (858) 202-9020 

	 	     
	 Email: pmaier@sequenom.com 

  
 20 

	 	 If to Bank:
	 Silicon Valley Bank 

	 	     
	 4370 La Jolla Village Drive, Suite 860 

	 	     
	 San Diego, CA 92130 

	 	     
	 Attn: Andy Pelletier Fax: (858) 622-1424 

	 	     
	 Email: APelletier@svb.com 

 11 CHOICE OF LAW, VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE 
 California law governs the Loan Documents without regard to principles of conflicts of law. Borrowers and Bank each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara
County, California; provided, however, that nothing in this Agreement shall be deemed to operate to preclude Bank from bringing suit or taking other legal action in any other jurisdiction to realize on the Collateral or any other security for the
Obligations, or to enforce a judgment or other court order in favor of Bank. Each Borrower expressly submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and each Borrower hereby waives any
objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as is deemed appropriate by such court. Each Borrower hereby waives
personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to such Borrower at the address
set forth in, or subsequently provided by such Borrower in accordance with, Section 10 of this Agreement and that service so made shall be deemed completed upon the earlier to occur of such Borrower’s actual receipt thereof or three
(3) Business Days after deposit in the U.S. mails, proper postage prepaid. 
 TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, EACH BORROWER AND BANK EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT,
BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. 

WITHOUT INTENDING IN ANY WAY TO LIMIT THE PARTIES’ AGREEMENT TO WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY, if
the above waiver of the right to a trial by jury is not enforceable, the parties hereto agree that any and all disputes or controversies of any nature between them arising at any time shall be decided by a reference to a private judge, mutually
selected by the parties (or, if they cannot agree, by the Presiding Judge of the Santa Clara County, California Superior Court) appointed in accordance with California Code of Civil Procedure Section 638 (or pursuant to comparable provisions of
federal law if the dispute falls within the exclusive jurisdiction of the federal courts), sitting without a jury, in Santa Clara County, California; and the parties hereby submit to the jurisdiction of such court. The reference proceedings shall be
conducted pursuant to and in accordance with the provisions of California Code of Civil Procedure §§ 638 through 645.1, inclusive. The private judge shall have the power, among others, to grant provisional relief, including without
limitation, entering temporary restraining orders, issuing preliminary and permanent injunctions and appointing receivers. All such proceedings shall be closed to the public and confidential and all records relating thereto shall be permanently
sealed. If during the course of any dispute, a party desires to seek provisional relief, but a judge has not been appointed at that point pursuant to the judicial reference procedures, then such party may apply to the Santa Clara County, California
Superior Court for such relief. The proceeding before the private judge shall be conducted in the same manner as it would be before a court under the rules of evidence applicable to judicial proceedings. The parties shall be entitled to discovery
which shall be conducted in the same manner as it would be before a court under the rules of discovery applicable to judicial proceedings. The private judge shall oversee discovery and may enforce all discovery rules and orders applicable to
judicial proceedings in the same manner as a trial court judge. The parties agree that the selected or appointed private judge shall have the power to decide all issues in the action or proceeding, whether of fact or of law, and shall report a
statement of decision thereon pursuant to California Code of Civil Procedure § 644(a). Nothing in this paragraph shall limit the right of any party at any time to exercise self-help remedies, foreclose against collateral, or obtain provisional
remedies. The private judge shall also determine all issues relating to the applicability, interpretation, and enforceability of this paragraph. 

  
 21 

 12 GENERAL PROVISIONS 

12.1 Successors and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns
of each party. No Borrower may assign this Agreement or any rights or obligations under it without Bank’s prior written consent (which may be granted or withheld in Bank’s discretion). Bank has the right, without the consent of or notice
to Borrowers, to sell, transfer, assign, negotiate, or grant participation in all or any part of, or any interest in, Bank’s obligations, rights, and benefits under this Agreement and the other Loan Documents. 

12.2 Indemnification. Borrowers agree to indemnify, defend and hold Bank and its directors, officers, employees,
agents, attorneys, or any other Person affiliated with or representing Bank (each, an “Indemnified Person”) harmless against: (a) all obligations, demands, claims, and liabilities (collectively, “Claims”)
claimed or asserted by any other party in connection with the transactions contemplated by the Loan Documents; and (b) all losses or expenses (including Bank Expenses) in any way suffered, incurred, or paid by such Indemnified Person as a
result of, following from, consequential to, or arising from transactions between Bank and Borrowers (including reasonable attorneys’ fees and expenses), except as to (a) or (b) for Claims and/or losses or expenses (including Bank
Expenses) directly caused by such Indemnified Person’s gross negligence or willful misconduct. 
 12.3
Time of Essence. Time is of the essence for the performance of all Obligations in this Agreement. 
 12.4
Severability of Provisions. Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision. 
 12.5 Correction of Loan Documents. Bank may correct patent errors and fill in any blanks in the Loan Documents consistent with the agreement of the parties so long as Bank provides Borrowers with
written notice of such correction and allows Borrowers at least ten (10) days to object to such correction. In the event of such objection, such correction shall not be made except by an amendment signed by both Bank and Borrowers. 

12.6 Amendments in Writing; Waiver; Integration. No purported amendment or modification of any Loan Document, or
waiver, discharge or termination of any obligation under any Loan Document, shall be enforceable or admissible unless, and only to the extent, expressly set forth in a writing signed by the party against which enforcement or admission is sought.
Without limiting the generality of the foregoing, no oral promise or statement, nor any action, inaction, delay, failure to require performance or course of conduct shall operate as, or evidence, an amendment, supplement or waiver or have any other
effect on any Loan Document. Any waiver granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether similar or dissimilar, or give rise to, or evidence, any
obligation or commitment to grant any further waiver. The Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and
negotiations between the parties about the subject matter of the Loan Documents merge into the Loan Documents. 

12.7 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on
separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. 
 12.8 Survival. All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than
inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been paid in full and satisfied. The obligation of Borrowers in Section 12.2 to indemnify Bank shall survive
until the statute of limitations with respect to such claim or cause of action shall have run. 
 12.9
Confidentiality. In handling any confidential information, Bank shall exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (a) to Bank’s Subsidiaries or
Affiliates; (b) to prospective transferees or purchasers of any interest in the Credit Extensions (provided, however, Bank shall use its best efforts to obtain any prospective transferee’s or purchaser’s agreement to

  
 22 

 
the terms of this provision); (c) as required by law, regulation, subpoena, or other order; (d) to Bank’s regulators or as otherwise required in connection with Bank’s
examination or audit; (e) as Bank considers appropriate in exercising remedies under the Loan Documents; and (f) to third-party service providers of Bank so long as such service providers have executed a confidentiality agreement with Bank
with terms no less restrictive than those contained herein. Confidential information does not include information that is either: (i) in the public domain or in Bank’s possession when disclosed to Bank, or becomes part of the public domain
after disclosure to Bank through no fault of Bank; or (ii) disclosed to Bank by a third party if Bank does not know that the third party is prohibited from disclosing the information. 

Bank may use confidential information for the development of databases, reporting purposes, and market analysis so long
as such confidential information is aggregated and anonymized prior to distribution unless otherwise expressly permitted by Borrowers. The provisions of the immediately preceding sentence shall survive the termination of this Agreement.

 12.10 Attorneys’ Fees, Costs and Expenses. In any action or proceeding between Borrowers and Bank
arising out of or relating to the Loan Documents, the prevailing party shall be entitled to recover its reasonable attorneys’ fees and other costs and expenses incurred, in addition to any other relief to which it may be entitled. 

12.11 Electronic Execution of Documents. The words “execution,” “signed,”
“signature” and words of like import in any Loan Document shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and enforceability as a
manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions
Act. 
 12.12 Captions. The headings used in this Agreement are for convenience only and shall not affect
the interpretation of this Agreement. 
 12.13 Construction of Agreement. The parties mutually
acknowledge that they and their attorneys have participated in the preparation and negotiation of this Agreement. In cases of uncertainty this Agreement shall be construed without regard to which of the parties caused the uncertainty to exist.

 12.14 Relationship. The relationship of the parties to this Agreement is determined solely by the
provisions of this Agreement. The parties do not intend to create any agency, partnership, joint venture, trust, fiduciary or other relationship with duties or incidents different from those of parties to an arm’s-length contract. 

12.15 Third Parties. Nothing in this Agreement, whether express or implied, is intended to: (a) confer any
benefits, rights or remedies under or by reason of this Agreement on any persons other than the express parties to it and their respective permitted successors and assigns; (b) relieve or discharge the obligation or liability of any person not
an express party to this Agreement; or (c) give any person not an express party to this Agreement any right of subrogation or action against any party to this Agreement. 

13 DEFINITIONS 
 13.1 Definitions. As used in the Loan Documents, the word “shall” is mandatory, the word “may” is permissive, the word “or” is not exclusive, the words
“includes” and “including” are not limiting, the singular includes the plural, and numbers denoting amounts that are set off in brackets are negative. As used in this Agreement, the following capitalized terms have the following
meanings: 
 “Account” is any “account” as defined in the Code with such additions to
such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to a Borrower or, on and after the date on which the Sequenom GmbH Share Pledge Documents are effective, to Sequenom Germany.

 “Account Debtor” is any “account debtor” as defined in the Code with such
additions to such term as may hereafter be made. 

  
 23 

 “Advance” or “Advances” means an advance
(or advances) under the Revolving Line. 
 “Affiliate” is, with respect to any Person, each
other Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any
Person that is a limited liability company, that Person’s managers and members. 

“Agreement” is defined in the preamble hereof. 

“Availability Amount” is (a) the lesser of (i) the Revolving Line or (ii) the amount
available under the Borrowing Base minus (b) the Dollar Equivalent amount of all outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit) plus an amount equal to the Letter of Credit Reserve, minus (c) the FX
Reduction Amount, minus (d) any amounts used for Cash Management Services, and minus (e) the outstanding principal balance of any Advances. 
 “Bank” is defined in the preamble hereof. 

“Bank Expenses” are all audit fees and expenses, costs, and expenses (including reasonable
attorneys’ fees and expenses) for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise
incurred with respect to Borrowers. 
 “Basic Rate” is the per annum rate of interest (based on
a year of 360 days) equal to the sum of (a) U.S. Treasury note yield to maturity for a term equal to the Treasury Note Maturity as reported in the Federal Reserve Statistical Release H.15-Selected Interest Rates under the heading “U.S.
Government Securities/Treasury Constant Maturities” on the applicable Funding Date, plus (b) three and one quarter percent (3.25%). (In the event Release H.15 is no longer published, Bank shall select a comparable publication to determine
the U.S. Treasury note yield to maturity.) 
 “Borrower(s)” is defined in the preamble hereof.

 “Borrower’s Books” are all of a Borrower’s books and records including ledgers,
federal and state tax returns, records regarding such Borrower’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. 

“Borrowing Base” is eighty percent (80%) of Eligible Accounts, as determined by Bank from
Borrowers’ most recent Transaction Report; provided, however, that Bank may decrease the foregoing percentage in its good faith business judgment based on events, conditions, contingencies, or risks which, as determined by Bank, may adversely
affect Collateral. 
 “Borrowing Base Report” is defined in Section 6.2(a). 

“Borrowing Resolutions” are, with respect to any Person, those resolutions substantially in the
form attached hereto as Exhibit D. 
 “Business Day” is any day that is not
a Saturday, Sunday or a day on which Bank is closed. 
 “Cash Equivalents” means
(a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing
no more than one (1) year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc.; (c) Bank’s certificates of deposit issued maturing no more
than one (1) year after issue; and (d) money market funds at least ninety-five percent (95%) of the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition.

 “Cash Management Services” is defined in Section 2.1.4. 

  
 24 

 “Code” is the Uniform Commercial Code, as the same may,
from time to time, be enacted and in effect in the State of California; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of
the Code, the definition of such term contained in Article or Division 9 shall govern; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with
respect to, Bank’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of California, the term “Code” shall mean the Uniform Commercial Code as enacted and in
effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions. 

“Collateral” is any and all properties, rights and assets of Borrowers described on Exhibit A.

 “Collateral Account” is any Deposit Account, Securities Account, or Commodity Account.

 “Commodity Account” is any “commodity account” as defined in the Code with such
additions to such term as may hereafter be made. 
 “Compliance Certificate” is that certain
certificate in the form attached hereto as Exhibit E. 
 “Contingent Obligation” is, for
any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation, in each case, directly or indirectly guaranteed,
endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from
any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but
“Contingent Obligation” does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if
not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. 

“Control Agreement” is any control agreement entered into among the depository institution at which a
Borrower maintains a Deposit Account or the securities intermediary or commodity intermediary at which a Borrower maintains a Securities Account or a Commodity Account, such Borrower, and Bank pursuant to which Bank obtains control (within the
meaning of the Code) over such Deposit Account, Securities Account, or Commodity Account. 

“Copyrights” are any and all copyright rights, copyright applications, copyright registrations and like
protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret. 

“Credit Extension” is any Advance, Letter of Credit, Term Loan, FX Forward Contract, amount utilized for
Cash Management Services, or any other extension of credit by Bank for Borrowers’ benefit. 

“Default Rate” is defined in Section 2.3(b). 

“Deferred Revenue” is all amounts received or invoiced in advance of performance under contracts
and not yet recognized as revenue. 
 “Deposit Account” is any “deposit
account” as defined in the Code with such additions to such term as may hereafter be made. 

“Designated Deposit Account” is a Borrower’s deposit account, account number
                            , maintained with Bank. 

  
 25 

 “Dollars,” “dollars”
or use of the sign “$” means only lawful money of the United States and not any other currency, regardless of whether that currency uses the “$” sign to denote its currency or may be readily converted into lawful money of
the United States. 
 “Dollar Equivalent” is, at any time, (a) with respect to any
amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Bank at such time on the basis of the then-prevailing rate of exchange
in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign Currency. 
 “Draw Period” is the period of time from the Effective Date through the earlier to occur of (a) August 31, 2012 or (b) an Event of Default. 

“Effective Date” is defined in the preamble hereof. 

“Eligible Accounts” means Accounts which arise in the ordinary course of a Borrower’s business that
meet all Borrowers’ representations and warranties in Section 5.3. Bank reserves the right at any time after the Effective Date to adjust any of the criteria set forth below and to establish new criteria in its good faith business
judgment. Unless Bank otherwise agrees in writing, Eligible Accounts shall not include: 
 (a) Accounts that the
Account Debtor has not paid within ninety (90) days of invoice date regardless of invoice payment period terms; 
 (b) Accounts owing from an Account Debtor, fifty percent (50%) or more of whose Accounts have not been paid within ninety (90) days of invoice date; 

(c) Accounts owing from an Account Debtor which does not have its principal place of business in the United States or
Canada unless such Accounts are otherwise Eligible Accounts and (i) covered in full by credit insurance satisfactory to Bank, less any deductible, (ii) supported by letter(s) of credit acceptable to Bank, (iii) supported by a guaranty
from the Export-Import Bank of the United States, or (iv) that Bank otherwise approves of in writing (collectively, “Eligible Foreign Accounts”); provided, however, that Advances on account of Eligible Foreign Accounts shall not
exceed an aggregate amount of Four Million Dollars ($4,000,000), after conversion to U.S. Dollars; provided further that the foregoing shall not apply to Accounts described in (d), below; 

(d) Accounts billed and/or payable outside of the United States, unless, notwithstanding the limitations in, and without
duplication with (c), above, on and after the date on which the Sequenom GmbH Share Pledge Documents are effective, such Accounts are Accounts billed and/or payable in Germany, in which case Advances on account of such Accounts shall not exceed an
aggregate amount of Three Million Dollars ($3,000,000), after conversion to U.S. Dollars; 
 (e) Accounts owing
from an Account Debtor to the extent that a Borrower is indebted or obligated in any manner to the Account Debtor (as creditor, lessor, supplier or otherwise - sometimes called “contra” accounts, accounts payable, customer deposits or
credit accounts), with the exception of customary credits, adjustments and/or discounts given to an Account Debtor by a Borrower in the ordinary course of its business; 

(f) Accounts for which the Account Debtor is a Borrower’s Affiliate, officer, employee, or agent; 

(g) Accounts with credit balances over ninety (90) days from invoice date; 

(h) Accounts owing from an Account Debtor which is a United States government entity or any department, agency, or
instrumentality thereof unless the relevant Borrower has assigned its payment rights to Bank and the assignment has been acknowledged under the Federal Assignment of Claims Act of 1940, as amended; 

  
 26 

 (i) Accounts for demonstration or promotional equipment, or in which goods
are consigned, or sold on a “sale guaranteed”, “sale or return”, “sale on approval”, or other terms if Account Debtor’s payment may be conditional; 

(j) Accounts owing from an Account Debtor where goods or services have not yet been rendered to the Account Debtor
(sometimes called memo billings or pre-billings); 
 (k) Accounts subject to contractual arrangements between a
Borrower and an Account Debtor where payments shall be scheduled or due according to completion or fulfillment requirements where the Account Debtor has a right of offset for damages suffered as a result of such Borrower’s failure to perform in
accordance with the contract (sometimes called contracts accounts receivable, progress billings, milestone billings, or fulfillment contracts); 
 (l) Accounts owing from an Account Debtor the amount of which may be subject to withholding based on the Account Debtor’s satisfaction of a Borrower’s complete performance (but only to the
extent of the amount withheld; sometimes called retainage billings); 
 (m) Accounts subject to trust
provisions, subrogation rights of a bonding company, or a statutory trust; 
 (n) Accounts owing from an Account
Debtor that has been invoiced for goods that have not been shipped to the Account Debtor unless Bank, the relevant Borrower, and the Account Debtor have entered into an agreement acceptable to Bank in its sole discretion wherein the Account Debtor
acknowledges that (i) it has title to and has ownership of the goods wherever located, (ii) a bona fide sale of the goods has occurred, and (iii) it owes payment for such goods in accordance with invoices from such Borrower (sometimes
called “bill and hold” accounts); 
 (o) Accounts for which the Account Debtor has not been invoiced;

 (p) Accounts that represent non-trade receivables or that are derived by means other than in the ordinary
course of a Borrower’s business; 
 (q) Accounts for which a Borrower has permitted Account Debtor’s
payment to extend beyond 90 days; 
 (r) Accounts subject to chargebacks or others payment deductions taken by
an Account Debtor; 
 (s) Accounts in which the Account Debtor disputes liability or makes any claim (but only
up to the disputed or claimed amount), or if the Account Debtor is subject to an Insolvency Proceeding, or becomes insolvent, or goes out of business; 
 (t) Accounts owing from an Account Debtor with respect to which Borrower has received Deferred Revenue (but only to the extent of such Deferred Revenue); 

(u) Accounts owing from an Account Debtor, including Affiliates, whose total obligations to a Borrower exceed twenty-five
percent (25%) of all Accounts, for the amounts that exceed that percentage, unless Bank approves in writing; and 
 (v) Accounts for which Bank in its good faith business judgment determines collection to be doubtful. 
 “Equipment” is all “equipment” as defined in the Code with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods,
vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 

  
 27 

 “ERISA” is the Employee Retirement Income Security Act of
1974, and its regulations. 
 “Event of Default” is defined in Section 8. 

“Exchange Act” is the Securities Exchange Act of 1934, as amended. 

“Foreign Currency” means lawful money of a country other than the United States.

 “Funding Date” is any date on which a Credit Extension is made to or for the
account of Borrowers which shall be a Business Day. 
 “FX Business Day” is any
day when (a) Bank’s Foreign Exchange Department is conducting its normal business and (b) the Foreign Currency being purchased or sold by a Borrower is available to Bank from the entity from which Bank shall buy or sell such Foreign
Currency. 
 “FX Forward Contract” is defined in Section 2.1.3.

 “FX Reduction Amount” is defined in Section 2.1.3. 

“FX Reserve” is defined in Section 2.1.3. 

“GAAP” is generally accepted accounting principles set forth in the opinions and pronouncements of the
Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant
segment of the accounting profession, which are applicable to the circumstances as of the date of determination. 
 “General Intangibles” is all “general intangibles” as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes
without limitation, all Intellectual Property, claims, income and other tax refunds, security and other deposits, payment intangibles, contract rights, options to purchase or sell real or personal property, rights in all litigation presently or
hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind. 

“Governmental Approval” is any consent, authorization, approval, order, license, franchise, permit,
certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 
 “Governmental Authority” is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or
other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization. 

“Indebtedness” is (a) indebtedness for borrowed money or the deferred price of property or
services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations.

 “Indemnified Person” is defined in Section 12.2. 

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy
Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

“Intellectual Property” means all of a Borrower’s right, title, and interest in and to the
following: 

  
 28 

 (a) its Copyrights, Trademarks and Patents; 

(b) any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented
inventions, know-how, operating manuals; 
 (c) any and all source code; 

(d) any and all design rights which may be available to a Borrower; 

(e) any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the
right, but not the obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and 
 (f) all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents. 
 “Inventory” is all “inventory” as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation all
merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of a Borrower’s custody or possession or in transit and
including any returned goods and any documents of title representing any of the above. 

“Investment” is any beneficial ownership interest in any Person (including stock, partnership interest
or other securities), and any loan, advance or capital contribution to any Person. 
 “Letter of
Credit” means a standby letter of credit issued by Bank or another institution based upon an application, guarantee, indemnity or similar agreement on the part of Bank as set forth in Section 2.1.2. 

“Letter of Credit Application” is defined in Section 2.1.2(b). 

“Letter of Credit Reserve” has the meaning set forth in Section 2.1.2(e). 

“Lien” is a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance
of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property. 

“Loan Documents” are, collectively, this Agreement, the Perfection Certificate, the Sequenom GmbH Share
Pledge Documents, any note, or notes or guaranties executed by a Borrower, and any other present or future agreement between a Borrower and/or for the benefit of Bank in connection with this Agreement, all as amended, restated, or otherwise
modified. 
 “Material Adverse Change” is (a) a material impairment in the perfection or
priority of Bank’s Lien in the Collateral or in the value of such Collateral; (b) a material adverse change in the business, operations, or condition (financial or otherwise) of Borrower; or (c) a material impairment of the prospect
of repayment of any portion of the Obligations; or (d) Bank determines, based upon information available to it and in its reasonable judgment, that there is a reasonable likelihood that Borrower shall fail to comply with one or more of the
financial covenants in Section 6 during the next succeeding financial reporting period. 
 “Monthly
Financial Statements” is defined in Section 6.2(c). 
 “Obligations” are a
Borrower’s obligations to pay when due any debts, principal, interest, Bank Expenses and other amounts such Borrower owes Bank now or later, whether under this Agreement, the Loan Documents, or otherwise, including, without limitation, all
obligations relating to letters of credit (including reimbursement obligations for drawn and undrawn letters of credit), cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings
begin and debts, liabilities, or obligations of such Borrower assigned to Bank, and to perform such Borrower’s duties under the Loan Documents. 

  
 29 

 “Operating Documents” are, for any Person, such
Person’s formation documents, as certified with the Secretary of State of such Person’s state of formation on a date that is no earlier than 30 days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in
current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar agreement), each of the
foregoing with all current amendments or modifications thereto. 
 “Operating Liquidity” means,
as of any date of determination, the amount of cash required to support Borrowers’ trailing three (3) month net cash operating losses. 
 “Patents” means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and
continuations-in-part of the same. 
 “Perfection Certificate” is defined in Section 5.1.

 “Permitted Distributions” are: 

(a) purchases of capital stock from former employees, consultants and directors pursuant to repurchase agreements,
employee stock options, restricted stock option or stock option plans, or other similar agreements in an aggregate amount not to exceed Two Hundred Fifty Thousand Dollars ($250,000) in any fiscal year provided that at the time of such purchase no
Event of Default has occurred and is continuing; 
 (b) distributions or dividends consisting solely of a
Borrower’s capital stock; 
 (c) purchases for value of any rights distributed in connection with any
stockholder rights plan; 
 (d) purchases of capital stock or options to acquire such capital stock with the
proceeds received from a substantially concurrent issuance of capital stock or convertible securities; 
 (e)
purchases of capital stock pledged as collateral for loans to employees; 
 (f) purchases of capital stock in
connection with the exercise of stock options or stock appreciation rights by way of cashless exercise or in connection with the satisfaction of withholding tax obligations; 

(g) purchases of fractional shares of capital stock arising out of stock dividends, splits or combinations or business
combinations; 
 (h) conversions of convertible securities into other securities pursuant to the terms of such
convertible securities or otherwise in exchange thereof; and 
 (i) distributions or dividends by a Subsidiary
to a Borrower, or by Sequenom Center to Parent. 
 “Permitted Indebtedness” is: 

(a) Borrowers’ Indebtedness to Bank under this Agreement and the other Loan Documents; 

(b) Indebtedness existing on the Effective Date and shown on the Perfection Certificate; 

(c) Subordinated Debt; 
 (d) unsecured Indebtedness to trade creditors incurred in the ordinary course of business; 
 (e) guaranties of Permitted Indebtedness; 

  
 30 

 (f) Indebtedness incurred as a result of endorsing negotiable instruments
received in the ordinary course of business; 
 (g) Indebtedness secured by Liens permitted under clauses
(a) and (c) of the definition of “Permitted Liens” hereunder; 
 (h) Indebtedness consisting
of interest rate, currency, or commodity swap agreements, interest rate cap or collar agreements or arrangements entered into in the ordinary course of business and designated to protect a Borrower or its Subsidiaries against fluctuations in
interest rates, currency exchange rates, or commodity prices; 
 (i) Indebtedness between a Borrower and any of
its Subsidiaries or among any of Borrowers’ Subsidiaries or between Borrowers; 
 (j) Indebtedness with
respect to documentary letters of credit; 
 (k) capitalized leases and purchase money Indebtedness not to
exceed Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate in any fiscal year secured by Liens permitted under clause (c) of the definition of “Permitted Liens”; 

(l) Indebtedness of entities acquired in any permitted merger or acquisition transaction; 

(m) Indebtedness of Borrowers or any of its Subsidiaries in the aggregate not in excess of $250,000 in the aggregate
arising from agreements providing for indemnification, adjustment to purchase price, escrows, earn-outs or similar obligations, or guaranties or letters of credit, surety bonds or performance bonds securing Borrowers’ or any such
Subsidiary’s performance pursuant to such agreements, in connection with Transfers not prohibited by Section 7.1 or acquisitions not prohibited by Section 7.3; 

(n) other Indebtedness not otherwise permitted by Section 7.4 not exceeding Two Hundred Fifty Thousand Dollars
($250,000) in the aggregate outstanding at any time; and 
 (o) extensions, renewals and refinancings of
Permitted Indebtedness, provided that the amount of such Indebtedness is not increased except by an amount equal to a reasonable premium or other reasonable amount paid in connection with such refinancing and by an amount equal to any existing, but
unutilized, commitment thereunder. 
 “Permitted Investments” are: 

(a) Investments (including, without limitation, Subsidiaries) shown on the Perfection Certificate and existing on the
Effective Date; 
 (b) Investments consisting of (i) marketable direct obligations issued or
unconditionally guaranteed by the United States or its agencies or any State maturing within 1 year from its acquisition, (ii) commercial paper maturing no more than 2 years after its creation and having the highest rating from either
Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc., and (iii) Bank’s certificates of deposit maturing no more than 2 years after issue; and (d) money market funds at least ninety-five percent
(95%) of the assets of which constitute Investments of the kinds described in clauses (i) through (iii) of this definition; 
 (c) Investments consisting of Cash Equivalents; 
 (d) Investments
consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of a Borrower; 
 (e) Investments consisting of deposit accounts, provided that Bank has a perfected security interest in such domestic deposit accounts to the extent required by Section 6.6; 

  
 31 

 (f) Investments accepted in connection with Transfers permitted by
Section 7.1; 
 (g) Investments by a Borrower in another Borrower; 

(h) Investments by a Borrower in domestic Subsidiaries, provided that such Subsidiaries are co-borrowers; 

(i) Investments by a Borrower in non-domestic Subsidiaries not to exceed One Million Dollars ($1,000,000) in the
aggregate in any fiscal year, provided that there is compliance with Section 6.11(b); 
 (j) Investments by
a Subsidiary in a Borrower or in another Subsidiary; provided that a non-domestic Subsidiary shall not in the aggregate retain bank (or other financial institution) balances in excess of Five Million Dollars ($5,000,000); 

(k) Investments approved by a Borrowers’ Board of Directors or otherwise pursuant to a Board-approved investment
policy; 
 (l) Investments consisting of Collateral Accounts in the name of a Borrower or any Subsidiary,
provided that Bank has a first priority, perfected security interest in such domestic Collateral Accounts to the extent required by Section 6.6(b); 
 (m) Investments consisting of extensions of credit to a Borrower’s or its Subsidiaries’ customers in the nature of accounts receivable, prepaid royalties or notes receivable in the ordinary
course of business arising from the sale or lease of goods, provision of services or licensing activities of such Borrower; 
 (n) Investments consisting of interest rate, currency, or commodity swap agreements, interest rate cap or collar agreements or arrangements entered into in the ordinary course of business and designated
to protect a Person against fluctuations in interest rates, currency exchange rates, or commodity prices; 
 (o)
Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity
securities of a Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by such Borrower’s Board of Directors; 
 (p) Investments permitted by Section 7.3; 
 (q) Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of
business; 
 (r) Investments consisting of notes receivable of, or prepaid royalties and other credit
extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business; provided that this paragraph (r) shall not apply to Investments of a Borrower in any Subsidiary; 

(s) Joint ventures, corporate collaborations, or strategic alliances in the ordinary course of a Borrower’s business
consisting of the licensing of technology, the development of technology or the providing of technical support, provided that any cash Investments by Borrowers do not exceed Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate in any
fiscal year; 
 (t) the formation or acquisition of Subsidiaries after the Effective Date, subject to the terms
and conditions of this Agreement; and 
 (u) other Investments not otherwise permitted by Section 7.7 not
exceeding $250,000 in the aggregate outstanding at any time. 

  
 32 

 “Permitted Liens” are: 

(a) Liens existing on the Effective Date and shown on the Perfection Certificate or arising under this Agreement and the
other Loan Documents; 
 (b) Liens for taxes, fees, assessments or other government charges or levies, either
(i) not due and payable or (ii) being contested in good faith and for which a Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of
1986, as amended, and the Treasury Regulations adopted thereunder; 
 (c) purchase money Liens (including
capital leases) (i) on Equipment acquired or held by a Borrower incurred for financing the acquisition of the Equipment securing no more than Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate amount outstanding, or
(ii) existing on Equipment when acquired, if the Lien is confined to the property and improvements and the proceeds of the Equipment; 
 (d) Liens of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long as such Liens secure liabilities in the aggregate amount
not to exceed Two Hundred Fifty Thousand Dollars ($250,000) and are not delinquent or remain payable without penalty or are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture
or sale of the property subject thereto; 
 (e) Liens to secure payment of workers’ compensation,
employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA); 

(f) Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in
(a) through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase; 

(g) leases or subleases of real property granted in the ordinary course of a Borrower’s business (or, if referring
to another Person, in the ordinary course of such Person’s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of a Borrower’s
business (or, if referring to another Person, in the ordinary course of such Person’s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Bank a security interest therein; 

(h) non-exclusive licenses of Intellectual Property granted to third parties in the ordinary course of business and other
non-perpetual licenses that could not result in a legal transfer of title of the licensed property but that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discrete geographical areas outside of
the United States; 
 (i) the rights of licensors under inbound licenses to a Borrower, subject to the terms and
conditions of this Agreement; 
 (j) Liens arising from attachments or judgments, orders, or decrees in
circumstances not constituting an Event of Default under Sections 8.4 and 8.7; 
 (k) Liens in favor of other
financial institutions arising in connection with a Borrower’s or a Subsidiary’s deposit and/or securities accounts held at such institutions, provided that Bank has a perfected security interest in the amounts held in such deposit and/or
securities accounts to the extent required by Section 6.6(b); 
 (l) Liens in favor of custom and revenue
authorities arising in the ordinary course of business as a matter of law to secure the payment of custom duties in connection with the importation of goods; 
 (m) deposits to secure the performance of bids, trade contracts (other than for borrowed money), contracts for the purchase of property, leases, statutory obligations, surety and appeal bonds, performance
bonds and other obligations of a like nature, in each case, incurred in the ordinary course of business and not representing an obligation for borrowed money; and 

  
 33 

 (n) easements, reservations, rights-of-way, restrictions, minor defects or
irregularities in title and other similar Liens affecting real property not interfering in any material respect with the ordinary course of the business of Borrowers. 

“Person” is any individual, sole proprietorship, partnership, limited liability company, joint venture,
company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“Prime Rate” is the Prime Rate published in the Money Rates section of the Western Edition of The Wall
Street Journal, provided, however, if such rate becomes unavailable, thereafter the “Prime Rate” is Bank’s most recently announced “prime rate,” even if it is not Bank’s lowest rate. 

“Registered Organization” is any “registered organization” as defined in the Code with such
additions to such term as may hereafter be made. 
 “Requirement of Law” is as to any Person,
the organizational or governing documents of such Person, and any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such
Person or any of its property or to which such Person or any of its property is subject. 

“Responsible Officer” is any of the Chief Executive Officer, President, Chief Financial Officer
and Controller of each Borrower.  
 “Restricted License” is any material license or
other agreement with respect to which a Borrower is the licensee (a) that prohibits or otherwise restricts a Borrower from granting a security interest in such Borrower’s interest in such license or agreement or any other property, or
(b) for which a default under or termination of which could interfere with the Bank’s right to sell any Collateral. 
 “Revolving Line” is an Advance or Advances in an amount equal to Ten Million Dollars ($10,000,000). 

“Revolving Line Early Termination Fee” is an amount equal to (i) three percent (3.00%) of the
Revolving Line at the time of termination if such termination occurs within twelve (12) months of the Effective Date, (ii) two percent (2.00%) of the Revolving Line at the time of termination if such prepayment occurs more than twelve
(12) months form the Effective Date but less than twenty-four (24) months from the Effective Date, and (iii) one percent (1.00%) of the Revolving Line at the time of termination if such termination occurs more than twenty four
(24) months from the Effective Date but less than thirty-six (36) months from the Effective Date. 

“Revolving Line Maturity Date” is
                             , 2014. 

“SEC” shall mean the Securities and Exchange Commission, any successor thereto, and any analogous
Governmental Authority. 
 “Securities Account” is any “securities account” as
defined in the Code with such additions to such term as may hereafter be made. 
 “Sequenom
Germany” means SEQUENOM Gesellschaft für Genomanalytik mbH, an entity organized under the laws of Germany and a wholly-owned Subsidiary of Parent. 

“Sequenom GmbH Share Pledge Documents” means that certain Share Pledge Agreement by and among Parent,
Sequenom Germany and Bank, and all documents and/or instruments executed and or delivered in connection therewith, all in form and content reasonably acceptable to Bank. 

  
 34 

 “Settlement Date” is defined in Section 2.1.3.

 “Shares” means (i) sixty-five percent (65%) of the issued and outstanding
capital stock, membership units or other securities owned or held of record by Parent in any Subsidiary of Parent which is not an entity organized under the laws of the United States or any territory thereof, and (ii) one hundred percent
(100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by Parent in any Subsidiary of Parent which is an entity organized under the laws of the United States or any territory thereof.

 “Subordinated Debt” is indebtedness incurred by a Borrower subordinated to all of such
Borrower’s now or hereafter indebtedness to Bank (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Bank entered into between Bank and the other creditor), on terms acceptable to Bank.

 “Subsidiary” is, as to any Person, a corporation, partnership, limited liability company or
other entity of which shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the board
of directors or other managers of such corporation, partnership or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person. Unless the
context otherwise requires, each reference to a Subsidiary herein shall be a reference to a Subsidiary of a Borrower. 
 “Term Loan” is a loan made by Bank pursuant to the terms of Section 2.1.5 hereof. 
 “Term Loan Payment/Advance Form” is that certain form attached hereto as Exhibit B. 
 “Term Loan Amount” is an amount equal to Twenty Million Dollars ($20,000,000). 
 “Term Loan Final Payment” is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest to occur of
(a) the Term Loan Maturity Date, (b) the acceleration of the Term Loans, or (c) the prepayment of the Term Loans, equal to the aggregate principal amount of all Term Loans advanced to Borrowers by Bank multiplied by the Term Loan
Final Payment Percentage. Notwithstanding the foregoing, if the aggregate principal amount of the Term Loans advanced to Borrower is less than Twelve Million Dollars ($12,000,000), the Term Loan Final Payment shall be Four Hundred Twenty Thousand
Dollars ($420,000). 
 “Term Loan Final Payment Percentage” is three and one half
percent (3.50%). 
 “Term Loan Maturity Date” is May 1, 2015. 

“Term Loan Payment” is defined in Section 2.1.5(b). 

“Term Loan Prepayment Fee” means with respect to any Term Loan subject to prepayment prior to
                            , 2012, whether by mandatory or voluntary prepayment, acceleration or
otherwise, an additional fee payable to the Bank in amount equal to two percent (2.00%) of the principal amount of such Term Loan prepaid. 
 “Trademarks” means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of
the business of a Borrower connected with and symbolized by such trademarks. 
 “Transaction
Report” is that certain report of transactions and schedule of collections in the form attached hereto as Exhibit C. 
 “Transfer” is defined in Section 7.1. 

“Treasury Note Maturity” is with respect to each Term Loan, the Draw Period remaining with respect to
such Term Loan, plus thirty three (33) months. 

  
 35 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed as of the Effective Date. 
 BORROWERS: 

 

			
	 SEQUENOM, INC.

		
	 By
	 	 /s/ Paul V. Maier        

	 Name:
	 	 Paul V. Maier

	 Title:
	 	 CFO

	
	 SEQUENOM CENTER FOR MOLECULAR MEDICINE, LLC

		
	 By
	 	 /s/ Paul V. Maier        

	 Name:
	 	 Paul V. Maier

	 Title:
	 	 President

		 	
	 BANK:

		 	
	 SILICON VALLEY BANK

	
		
	 By
	 	 
	 Name:
	 	 
	 Title:
	 	 

 [Signature page to Loan and Security Agreement] 

 EXHIBIT A – COLLATERAL DESCRIPTION 

The Collateral consists of all of each Borrower’s right, title and interest in and to the following personal property: 

All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or rights to payment of
money, leases, license agreements, franchise agreements, General Intangibles (except as provided below), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit
accounts, all Pledged CDs, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or
hereafter acquired, wherever located; and 
 all Borrower’s Books relating to the foregoing, and any and
all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

 Notwithstanding the foregoing, the Collateral does not include: 

(i) any Intellectual Property; provided, however, the Collateral shall include all Accounts and all proceeds of
Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are
proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Bank’s security interest in such Accounts and
such other property of Borrower that are proceeds of the Intellectual Property; 
 (ii) more than 65% of the
voting power entitled to vote of all classes of capital stock of any Subsidiary not organized under the laws of the United States or any state or territory thereof or the District of Columbia; or 

(iii) any Inbound License (as defined below) in which a Borrower has any right, title or interest if and to the extent
such Inbound License includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of such Borrower therein would be prohibited and would, in and of itself, cause or result
in a default thereunder enabling the licensor to enforce any remedy with respect thereto; provided that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation
hereunder of a security interest in such Inbound License or (ii) such prohibition would be rendered ineffective pursuant to Section 9-408 of the California Uniform Commercial Code; provided further that immediately upon the
ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and such Borrower shall be deemed to have granted on the date hereof a security interest in, all its rights, title and interests in and to such Inbound
License as if such provision had never been in effect; or 
 (iv) the collateral described on the following
UCC-1 Financing Statements, until such time as such Financing Statement is terminated or the indebtedness evidenced thereby has been satisfied in full: 
 (A) UCC-1 financing statement (file no. 62404994) filed by Citicorp Vendor Finance, Inc. against Parent with the Delaware Secretary of State on July 12, 2006; 

(B) UCC-1 financing statement (file no. 74039094) filed by General Electric Capital Corporation against Parent with the
Delaware Secretary of State on October 4, 2007; 
 (C) UCC-1 financing statement (file no. 80095792) filed
by General Electric Capital Corporation against Parent with the Delaware Secretary of State on January 4, 2008; 
 (D) UCC-1 financing statement (file no. 81188653) filed by General Electric Capital Corporation against Parent with the Delaware Secretary of State on March 31, 2008; 

(E) UCC-1 financing statement (file no. 82522108) filed by General Electric Capital Corporation against Parent with the
Delaware Secretary of State on July 16, 2008; 
 (F) UCC-1 financing statement (file no. 83392386) filed by
Cisco Systems Capital Corporation against Parent with the Delaware Secretary of State on October 7, 2008; 

  
 1 

 (G) UCC-1 financing statement (file no. 92583383) filed by U.S. Bancorp
against Parent with the Delaware Secretary of State on August 12, 2009; and 
 (H) UCC-1 financing
statement (file no. 2009076288-8) filed by LHPT, Inc. dba Mr. Copy against Sequenom Center with the Michigan Secretary of State on May 20, 2009. 
 For purposes hereof, the term “Inbound Licenses” means: (i) Research Agreement dated August 3, 2004 between The Chinese University of Hong Kong (“CUHK”) and Parent (Agreement
No. TS042063), (ii) License Agreement dated November 1, 2006 between CUHK and Parent (Agreement No. TS052504), (iii) License Agreement dated December 22, 2006 between CUHK and Parent (Agreement No. TS063403), (iv) License
Agreement dated January 5, 2007 between CUHK and Parent (Agreement No. TS063596 (v) Sponsored Research Agreement dated March 6, 2008 between CUHK and Parent (Agreement No. TS084290), (vi) License Agreement dated
September 16, 2008 between CUHK and Parent (Agreement No. TS094849), (vii) Sponsored Research Agreement between CUHK and Parent dated May 3, 2011 (Agreement No. TS116377), (viii) License Agreement between CUHK and Parent dated
May 3, 2011 (Agreement No. TS116378), (ix) License Agreement between CUHK and Parent dated May 3, 2011 (Agreement No. TS116379), (x) Exclusive License of Technology Agreement (ISIS Project No. 046) dated October 14,
2005 between ISIS Innovation Limited and Parent, in each case, as amended from time to time. 
 Pursuant to the
terms of a certain negative pledge arrangement with Bank, Borrower has agreed not to encumber any of its Intellectual Property without Bank’s prior written consent except as permitted under the Agreement. 

  
 2 

 EXHIBIT B – TERM LOAN PAYMENT/ADVANCE REQUEST FORM 

DEADLINE FOR SAME DAY PROCESSING IS
NOON PACIFIC TIME* 
  

			
	 Fax To:
	  	Date:
                                         
       

  

					
	 LOAN PAYMENT:
	  	 	  	 
	 	  	             SEQUENOM, INC. on behalf of all Borrowers
	  	 
	 		 
	
From Account #                         
                                         
  
	  	
To Account #                         
                                         
 
	  	 
	 (Deposit Account #)
	  	(Loan Account #)	  	 
	 Principal $
                                         
                                  
	  	 and/or Interest
$                                       
                         
	  	 
	 		 
	 Authorized Signature:
                                         
                  
	  	
Phone Number:                    
                               
	  	 
	
Print Name/Title:                 
                                         
         
	  		  	 
	 	  	 	  	 

  

					
	 LOAN ADVANCE:
	  	 	  	 
	 
	 Complete Outgoing Wire Request
section below if all or a portion of the funds from this loan advance are for an outgoing wire.

	 		 
	
From Account #                         
                                         
  
	  	
To Account #                         
                                         
 
	  	 
	 (Loan Account #)
	  	(Deposit Account #)	  	 
	 		 
	 Amount of Advance
$                                         
                   
	  		  	 
	 
	 All Borrowers’ representations and
warranties in the Loan and Security Agreement are true, correct and complete in all material respects on the date of the request for an advance; provided, however, that such materiality qualifier shall not be applicable to any representations and
warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material
respects as of such date:

	 		 
	 Authorized Signature:
                                         
                  
	  	
Phone Number:                    
                               
	  	 
	
Print Name/Title:                 
                                         
         
	  		  	 
	 	  	 	  	 

  

					
	 OUTGOING WIRE
REQUEST:
	  	 	  	 
	 
	 Complete only if all or a portion of
funds from the loan advance above is to be wired.

	 Deadline for same day processing is noon,
Pacific Time

	 		 
	 Beneficiary Name:
                                         
                                   
	  	 Amount of Wire: $
                                         
                              
	  	 
	 Beneficiary Bank:
                                         
                                     
	  	 Account Number:
                                         
                                
	  	 
	 City and State:
                                         
                                         

	  		  	 
	 		 
	 Beneficiary Bank Transit (ABA)#:
                                         
              
	  	 Beneficiary Bank Code (Swift, Sort, Chip, etc.):
                               
	  	 
	 	  	 (For International Wire Only)
	  	 
	 		 
	 Intermediary Bank:
                                         
                                   
	  	 Transit (ABA) #:
                                         
                                
	  	 
	 For Further Credit to:
                                         
                                         
                                         
                                         
            
	  	 
	 	 
	 Special Instruction:
                                         
                                         
                                         
                                         
               
	  	 
	 
	 By signing below, I (we) acknowledge
and agree that my (our) funds transfer request shall be processed in accordance with and subject to the terms
and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and
executed by me (us).

	 		 
	 Authorized Signature:
                                         
                                
	  	 2nd Signature (if required):
                                        
                      
	  	 
	
Print Name/Title:                 
                                         
                     
	  	
Print Name/Title:                 
                                         
                
	  	 
	 Telephone #:
                                         
                                         
   
	  	 Telephone #:
                                         
                                      
	  	 
	 	  	 	  	 

  
  

* Unless otherwise provided for an Advance bearing interest at LIBOR 

  
 1 

 EXHIBIT C – TRANSACTION REPORT 

[EXCEL SPREADSHEET TO BE PROVIDED SEPARATELY BY LENDING OFFICER.] 

  
 1 

 EXHIBIT D 

BORROWING RESOLUTIONS 
 Corporation Resolutions and Incumbency Certification 
 Authority to
Procure Loans 
  
 I
certify that I am the duly elected and qualified Secretary of Sequenom, Inc.; that the following is a true and correct copy of resolutions duly adopted by the Board of Directors of the Corporation in accordance with its bylaws and applicable
statutes. 
 Copy of Resolutions: 
 Be it Resolved, That: 
  

	 1.
	 Any one (1) of the following HARRY F. HIXSON, JR., CEO, PAUL V. MAIER, CFO (insert titles only) of the Corporation are/is authorized,
for, on behalf of, and in the name of the Corporation to: 

  

	 	 (a)
	 Negotiate and procure loans, letters of credit and other credit or financial accommodations from Silicon Valley Bank (“Bank”), a
California corporation, from time to time; 

  

	 	 (b)
	 Discount with the Bank, commercial or other business paper belonging to the Corporation made or drawn by or upon third parties;

  

	 	 (c)
	 Purchase, sell, exchange, assign, endorse for transfer and/or deliver certificates and/or instruments representing stocks, bonds, evidences of
Indebtedness or other securities owned by the Corporation, whether or not registered in the name of the Corporation; 

  

	 	 (d)
	 Give security for any liabilities of the Corporation to the Bank by grant, security interest, assignment, lien, deed of trust or mortgage upon any
real or personal property, tangible or intangible of the Corporation; and 

  

	 	 (e)
	 Execute and deliver in form and content as may be required by the Bank any and all notes, evidences of Indebtedness, applications for letters of
credit, guaranties, subordination agreements, loan and security agreements, financing statements, assignments, liens, deeds of trust, mortgages, trust receipts and other agreements, instruments or documents to carry out the purposes of these
Resolutions, ,and any and all amendments or modifications thereto, any or all of which may relate to all or to substantially all of the Corporation’s property and assets. 

 

	 2.
	 Said Bank be and it is authorized and directed to pay the proceeds of any such loans or discounts as directed by the persons so authorized to sign,
whether so payable to the order of any of said persons in their individual capacities or not, and whether such proceeds are deposited to the individual credit of any of said persons or not; 

 

	 3.
	 Any and all agreements, instruments and documents previously executed and acts and things previously done to carry out the purposes of these
Resolutions are ratified, confirmed and approved as the act or acts of the Corporation. 

  

	 4.
	 These Resolutions shall continue in force, and the Bank may consider the holders of said offices and their signatures to be and continue to be as
set forth in a certified copy of these Resolutions delivered to the Bank, until notice to the contrary in writing is duly served on the Bank (such notice to have no effect on any action previously taken by the Bank in reliance on these Resolutions).

  

	 5.
	 Any person, corporation or other legal entity dealing with the Bank may rely upon a certificate signed by an officer of the Bank to effect that
these Resolutions and any agreement, instrument or document executed pursuant to them are still in full force and effect and binding upon the Corporation. 

 

	 6.
	 The Bank may consider the holders of the offices of the Corporation and their signatures, respectively, to be and continue to be as set forth in the
Certificate of the Secretary of the Corporation until notice to the contrary in writing is duly served on the Bank. 

 I further certify that the above Resolutions are in full force and effect as of the date of this Certificate; that these Resolutions and any borrowings or financial accommodations under these Resolutions
have been properly noted in the corporate books and records, and have not been rescinded, annulled, revoked or modified; that neither the foregoing Resolutions nor any actions to be taken pursuant to them are or will be in contravention of any
provision of the articles of incorporation or bylaws of the Corporation or of any agreement, indenture or other instrument to which the Corporation is a party or by which it is bound; and that neither the articles of incorporation nor bylaws of the
Corporation nor any agreement, indenture or other instrument to which the Corporation is a party or by which it is bound require the vote or consent of shareholders of the Corporation to authorize any act, matter or thing described in the foregoing
Resolutions. 

  
 1 

 I further certify that the following named persons have been duly elected to the offices set
opposite their respective names, that they continue to hold these offices at the present time, and that the signatures which appear below are the genuine, original signatures of each respectively: 

(PLEASE SUPPLY GENUINE SIGNATURES OF AUTHORIZED SIGNERS BELOW) 

 

					
	NAME (Type or Print)	  	TITLE	  	SIGNATURE
			
	 HARRY F. HIXSON, JR.
	  	 CEO
	  	/s/ HARRY F. HIXSON, JR.
			
	 PAUL V. MAIER
	  	 CFO
	  	/s/ PAUL V. MAIER
			
	  
	  	  
	  	  

			
	  
	  	  
	  	  

			
	  
	  	  
	  	  

			
	  
	  	  
	  	  

			
	  
	  	  
	  	  

 In Witness Whereof, I have affixed my name as Secretary and have caused the corporate seal (where
available) of said Corporation to be affixed on MAY 31, 2011. 
  

			
		
	/s/    Clark W. Neumann	 	 
	Secretary	 	

 *** 
  

			
	 The Above Statements are Correct.
	 	 /s/    Clark W. Neumann

		 	 SIGNATURE OF OFFICER OR DIRECTOR OR, IF
NONE. A SHAREHOLDER OTHER THAN SECRETARY WHEN SECRETARY IS AUTHORIZED TO
SIGN ALONE.

 Failure to complete the above when the Secretary is authorized to sign alone shall constitute a
certification by the Secretary that the Secretary is the sole Shareholder, Director and Officer of the Corporation. 

  
 2 

 

  
 LIMITED LIABILITY COMPANY BORROWING CERTIFICATE 

BORROWER: SEQUENOM CENTER FOR MOLECULAR MEDICINE,
LLC                     DATE:
                    , 2011 
 BANK:   Silicon Valley Bank 

I/We hereby certify as follows, as of the date set forth above: 

Borrower is duly organized, existing and in good standing as a 

  Sole     member-managed 

               manager-managed

 limited liability company under the laws of the State of Michigan, and that we are all of Borrower’s

      X       members 

               managers 

and that Borrower’s name shown above is the exact legal name of Borrower. 

We/ I certify that at a duly held meeting of Borrower (or by other authorized company action) the
following resolutions were adopted. Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Bank may rely on them until Bank receives written notice of
revocation from Borrower. 
 RESOLVED, that any one
of the following individuals, whose names, titles and signatures are below, may act on behalf of Borrower: 
  

											
	 Name
	 		 	Title	 		 	Signature	  	 Authorized to Add or
 Remove Signatories

						
	 PAUL V. MAIER
	 		 	PRESIDENT	 		 	/s/ PAUL V. MAIER	  	 ̈
						
	 	 		 	 	 		 	 	  	 ̈
						
	 	 		 	 	 		 	 	  	 ̈
						
	 	 		 	 	 		 	 	  	 ̈

 RESOLVED FURTHER, that any
one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower. 

RESOLVED FURTHER, that such individuals may, on behalf of Borrower: 

Borrow Money. Borrow money from Bank. 

Execute Loan Documents. Execute any loan documents Bank requires. 

Grant Security. Grant Bank a security interest in any of Borrower’s assets. 

Negotiate Items. Negotiate or discount all drafts, trade acceptances, promissory notes, or other
indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds. 
 Letters of
Credit. Apply for letters of credit from Bank. 

  
 1 

 Foreign Exchange Contracts. Execute spot or forward foreign exchange
contracts. 
 Further Acts. Designate other individuals to request advances, pay fees and
costs and execute other documents or agreements (including documents or agreement that waive Borrowers right to a jury trial) they believe to be necessary to effectuate such resolutions. 

RESOLVED FURTHER, that all acts authorized by the above resolutions and any prior
acts relating thereto are ratified. 
 The persons listed above are Borrower’s members/managers or employees with their
titles and signatures shown next to their names. 
 The execution, delivery, and performance of this Certificate are within the
undersigned’s powers, have been duly authorized, and are not in conflict with nor constitute a breach of any provision contained in the undersigned’s operating agreement, nor will they constitute an event of default under any material
agreement to which the undersigned is a party or by which the undersigned is bound. No consent from any other party is required to execute this Certificate. 
 We/I certify that the persons listed below are Borrower’s members/managers with their signatures shown above their names. 
 We/I have read all the provisions of this Limited Liability Company Borrowing Certificate, and we certify and agree to its terms. 

 

							
	 /s/ Clarke W. Neumann
	  		  	 	  	
	 Clarke W. Neumann
	  		  	 	  	
	     [print name]
	  		  	 [print name]
	  	
	 SECRETARY
	  		  	 	  	
	     [title]
	  		  	 [title]
	  	
				
	 	  		  	 	  	
	 	  		  	 	  	
	     [print name]
	  		  	 [print name]
	  	
	 	  		  	 	  	
	     [title]
	  		  	 [title]
	  	

  
 2 

 EXHIBIT E 

COMPLIANCE CERTIFICATE 
  

											
	 TO:
	 	 SILICON VALLEY BANK
	  		  	 Date:  
	 	 	  	
	 FROM:
	 	 SEQUENOM, INC.
	  		  		 		  	

 The undersigned authorized officer of SEQUENOM, INC. (a “Borrower”) certifies
that under the terms and conditions of the Loan and Security Agreement between Borrowers and Bank (the “Agreement”): 
 (1) Borrowers are in complete compliance for the period
ending                                with all required covenants except as noted
below; (2) there are no Events of Default except as noted below; (3) all representations and warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however, that such
materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a
specific date shall be true, accurate and complete in all material respects as of such date; (4) each Borrower, and each of their Subsidiaries, have timely filed all required tax returns and reports or extensions therefor, and each Borrower has
timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by such Borrower except as otherwise permitted pursuant to the terms of Section 5.9 of the Agreement; and (5) no Liens have been levied
or claims made against a Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which such Borrower has not previously provided written notification to Bank. 

Attached are the required documents supporting the certification. The undersigned certifies that these are prepared in
accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes. The undersigned acknowledges that no borrowings may be requested at any time or date of determination that Borrowers
are not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the
Agreement. 
 Please indicate compliance status by circling Yes/No under “Complies” column. 

 

					
	 Reporting Covenant
	  	Required	 	Complies
	 	 	 
	 	  	 	 	 
	 Monthly financial statements with
Compliance Certificate
	  	 Monthly within 30 days
	 	Yes    
No
	 Annual financial statement (CPA Audited) + CC
	  	 FYE within 120 days
	 	Yes    No
	 Annual financial projections
	  	 FYE within 60 days
	 	 
	 10-Q, 10-K and 8-K
	  	 Within 5 days after filing with SEC
	 	Yes    No
	 Deferred Revenue reports
	  	 Monthly within 30 days, if applicable
	 	 
	 Borrowing Base Certificate A/R & A/P Agings
	  	 Monthly within 30 days
	 	Yes    No
	 
	 
	 
	 

  

							
	
Financial Covenant
	 	 Required
	 	 Actual
	 	Complies
	 	 	 	 
	 	 	 	 	 	 	 
	 Maintain on a Monthly Basis:
	 	 	 	 	 	 
	 Minimum Liquidity
	 	 *see section 6.7
	 	
$                
	 	Yes    
No

 The following financial covenant analysis and information
set forth in Schedule 1 attached hereto are true and accurate as of the date of this Certificate. 
 The following are the exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions to note.”) 

  
 1 

	
	 
	
	 
	
	 

 

							
		 	 SEQUENOM, INC. on behalf of itself and the other
Borrowers

				
		 	 By:
	  	 	 	

							
	  	 	 Name:
	  	  	 	 

							
	  	 	 Title:
	  	  	 	 

 BANK USE ONLY 

 

					
	 Received by:
	  	 	 	

					
		  	AUTHORIZED SIGNER    	 	

  

					
	 Date:
	  	 	 	

  

					
	 Verified:
	  	 	 	
		  	AUTHORIZED SIGNER    	 	

  

					
	 Date:
	  	 	 	

 Compliance Status:            
Yes         No 

 

  
 2 

 Schedule 1 to Compliance Certificate 

Financial Covenants of Borrowers 
   In the event of a conflict between this Schedule and the Loan Agreement, the terms of the Loan Agreement shall govern. 
 Dated:
                                        
             
 I. Minimum Liquidity (Section 6.7)

 Required:             An amount equal to or greater than
(i) the sum of all Indebtedness to Bank plus (ii) Operating Liquidity 
 Actual: 

 

							
				
		 	 A.
	 	 Unrestricted cash and marketable securities
	 	 $                

				
		 	 B.
	 	 Availability Amount
	 	 $                

				
		 	 C.
	 	 Liquidity (line A plus line B)
	 	 $                

				
		 	 D.
	 	 Indebtedness to Bank
	 	 $                

				
		 	 E.
	 	 Operating Liquidity (trailing 3 month)
	 	 $                

				
		 	 F.
	 	 Line D plus line E
	 	 $                

 Is line C equal to or greater than line F? 

 

			
	
                  No, not in
compliance                    
	  	                          
            Yes, in compliance

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]